1
|
Laakmann E, Riecke K, Neunhöffer T, Park-Simon TW, Weide R, Polasik A, Schmidt M, Puppe J, Fasching P, Hesse T, Decker T, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Mueller V, Witzel I. 269P Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC registry. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
2
|
Hägele M, Müller KR, Denkert C, Schneeweiss A, Sinn B, Untch M, Van Mackelenbergh M, Jackisch C, Nekljudova V, Karn T, Alber M, Marmé F, Schem C, Stickeler E, Fasching P, Mueller V, Weber K, Lederer B, Loibl S, Klauschen F. 68MO Generalization of a deep learning model for HER2 status predictions on H&E-stained whole slide images derived from 3 neoadjuvant clinical studies. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
3
|
Greil R, Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey L, Chien AJ, Curigliano G, DiGiovanna MP, Gelmon K, Hortobagyi G, Hurvitz S, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Aktualisierte Ergebnisse von Tucatinib versus Placebo in Kombination
mit Trastuzumab und Capecitabin bei Patienten mit vorbehandeltem, metastasierten
HER2-positiven Brustkrebs mit ZNS-Metastasen (HER2CLIMB). Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1746156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- R Greil
- Dritte medizinische Abteilung, Paracelsus Medizinische
Universität Salzburg, Salzburger Krebsforschungsinstitut –
Zentrum für Klinische Krebs- und Immunologiestudien und Cancer Cluster
Salzburg, Salzburg. Österreich
| | - N U Lin
- Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| | - R K Murthy
- MD Anderson Cancer Center, Houston, Texas, USA
| | - V Abramson
- Vanderbilt University Medical Center, Nashville, Tennessee,
USA
| | - C Anders
- Duke Cancer Institute, Durham, North Carolina, USA
| | | | - P L Bedard
- University Health Network, Princess Margaret Cancer Centre, Toronto,
Ontario, Kanada
| | - V Borges
- University of Colorado Cancer Center, Aurora, Colorado,
USA
| | - D Cameron
- Edinburgh Cancer Research Centre, Edinburgh, Vereinigtes
Königreich
| | - L Carey
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North
Carolina, USA
| | - A J Chien
- University of California at San Francisco, San Francisco, Kalifornien,
USA
| | - G Curigliano
- Istituto Europeo di Oncologia, IRCCS, University of Milano, Mailand,
Italien
| | | | - K Gelmon
- British Columbia Cancer – Vancouver Centre, British Columbia,
Kanada
| | | | - S Hurvitz
- UCLA Medical Center/Jonsson Comprehensive Cancer Center, Los
Angeles, Kalifornien, USA
| | - I Krop
- Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| | - S Loi
- Peter MacCallum Cancer Centre, Melbourne, Australien
| | - S Loibl
- Deutsche Brust-Gruppe, Neu-Isenburg. Deutschland
| | - V Mueller
- Universitätsklinikum Hamburg-Eppendorf, Hamburg,
Deutschland
| | - M Oliveira
- Hospital Universitario Vall D‘Hebron, Barcelona,
Spanien
| | - E Paplomata
- Carbone Cancer Center University of Wisconsin, Madison, Wisconsin,
USA
| | - M Pegram
- Stanford Comprehensive Cancer Institute Palo Alto, Kalifornien,
USA
| | - D Slamon
- UCLA Medical Center/Jonsson Comprehensive Cancer Center, Los
Angeles, Kalifornien, USA
| | - A Zelnak
- Northside Hospital, Sandy Springs, Georgia, USA
| | - J Ramos
- Seagen Inc., Bothell, Washington, USA
| | - W Feng
- Seagen Inc., Bothell, Washington, USA
| | - E. Winer
- Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| |
Collapse
|
4
|
Vladimirova V, Schneeweiss A, Jackisch C, Weber K, Denkert C, Schmatloch S, Karn T, Fasching P, Braun S, Szeto C, Sinn B, van Mackelenbergh M, Schem C, Stickeler E, Soon-Shiong P, Marmé F, Mueller V, Untch M, Nekljudova V, Loibl S. 21P BACH1 and HIF1α predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
5
|
Mueller V, Ruhnke M, Hoffmann O, Grafe A, Tomé O, Fett W, Bruch HR, Sommer AK, Schneeweiss A. 98P Final results from AVANTI, a multicentre German observational study of first-line bevacizumab (BEV) + chemotherapy (CT) in >2000 patients (pts) with advanced breast cancer (aBC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
6
|
Laakmann E, Witzel I, Neunhöffer T, Park-Simon TW, Weide R, Riecke K, Polasik A, Schmidt M, Puppe J, Mundhenke C, Lübbe K, Hesse T, Thill M, Zahm DM, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Mueller V. 95MO Characteristics of patients with brain metastases from HER2-positive breast cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
7
|
Leichsenring J, Vladimirova V, Solbach C, Karn T, Ataseven B, Sinn B, Barinoff J, Mueller V, Blohmer JU, Schem C, Engels K, Marmé F, Fissler-Eckhoff A, Fasching P, Stickeler E, van Mackelenbergh M, Denkert C, Stenzinger A, Loibl S, Gröschel S. 28P EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
8
|
Furlanetto J, Denkert C, Untch M, Sinn B, Lederer B, Schneeweiss A, Mueller V, van Mackelenbergh M, Stickeler E, Fasching P, Schem C, Karn T, Marmé F, Nekljudova V, Loibl S. 17P Impact of body mass index (BMI) on prognostic and predictive value of stromal tumour-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): A pooled analysis of six neoadjuvant trials. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
9
|
Bell AR, Wrathall DJ, Mueller V, Chen J, Oppenheimer M, Hauer M, Adams H, Kulp S, Clark PU, Fussell E, Magliocca N, Xiao T, Gilmore EA, Abel K, Call M, Slangen ABA. Migration towards Bangladesh coastlines projected to increase with sea-level rise through 2100. Environ Res Lett 2021; 16:024045. [PMID: 36034333 PMCID: PMC9415774 DOI: 10.1088/1748-9326/abdc5b] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
To date, projections of human migration induced by sea-level change (SLC) largely suggest large-scale displacement away from vulnerable coastlines. However, results from our model of Bangladesh suggest counterintuitively that people will continue to migrate toward the vulnerable coastline irrespective of the flooding amplified by future SLC under all emissions scenarios until the end of this century. We developed an empirically calibrated agent-based model of household migration decision-making that captures the multi-faceted push, pull and mooring influences on migration at a household scale. We then exposed ~4800 000 simulated migrants to 871 scenarios of projected 21st-century coastal flooding under future emissions pathways. Our model does not predict flooding impacts great enough to drive populations away from coastlines in any of the scenarios. One reason is that while flooding does accelerate a transition from agricultural to non-agricultural income opportunities, livelihood alternatives are most abundant in coastal cities. At the same time, some coastal populations are unable to migrate, as flood losses accumulate and reduce the set of livelihood alternatives (so-called 'trapped' populations). However, even when we increased access to credit, a commonly-proposed policy lever for incentivizing migration in the face of climate risk, we found that the number of immobile agents actually rose. These findings imply that instead of a straightforward relationship between displacement and migration, projections need to consider the multiple constraints on, and preferences for, mobility. Our model demonstrates that decision-makers seeking to affect migration outcomes around SLC would do well to consider individual-level adaptive behaviors and motivations that evolve through time, as well as the potential for unintended behavioral responses.
Collapse
Affiliation(s)
- A R Bell
- Department of Earth and Environment, Boston University, Boston, MA 02215, United States of America
- Department of Environmental Studies, New York University, New York, NY 10012, United States of America
| | - D J Wrathall
- College of Earth, Ocean and Atmospheric Sciences, Oregon State University, Corvallis, OR 97331-5503, United States of America
| | - V Mueller
- School of Politics and Global Studies, Arizona State University, Tempe, AZ 85287-3902, United States of America
- International Food Policy Research Institute, Washington, DC 20005, United States of America
| | - J Chen
- Department of Agricultural, Environmental, and Development Economics, The Ohio State University, Columbus, OH 43210, United States of America
| | - M Oppenheimer
- School of Public and International Affairs and Department of Geosciences, Princeton University, Princeton, NJ 08544-1013, United States of America
| | - M Hauer
- Department of Sociology, Florida State University, Tallahassee, FL 32306, United States of America
| | - H Adams
- Department of Geography, King's College London, London WC2R 2LS, United Kingdom
| | - S Kulp
- Climate Central, Princeton, NJ 08542, United States of America
| | - P U Clark
- College of Earth, Ocean and Atmospheric Sciences, Oregon State University, Corvallis, OR 97331-5503, United States of America
- School of Geography and Environmental Sciences, University of Ulster, Coleraine, Northern Ireland BT52 1SA, United Kingdom
| | - E Fussell
- Population Studies and Training Center and the Institute at Brown on Environment and Society, Brown University, Providence, RI 02912, United States of America
| | - N Magliocca
- Department of Geography, University of Alabama, Tuscaloosa, AL 35401, United States of America
| | - T Xiao
- School of Public and International Affairs and Department of Geosciences, Princeton University, Princeton, NJ 08544-1013, United States of America
| | - E A Gilmore
- Department of International Development, Community and Environment, Clark University, Worcester, MA 01610-1477, United States of America
| | - K Abel
- College of Earth, Ocean and Atmospheric Sciences, Oregon State University, Corvallis, OR 97331-5503, United States of America
| | - M Call
- USAID, Washington, DC, United States of America
| | - A B A Slangen
- Department of Estuarine and Delta Systems, NIOZ Royal Netherlands Institute for Sea Research, Yerseke 4401 NT, The Netherlands
| |
Collapse
|
10
|
Jaeger A, Woelber L, Prieske K, Trepte C, Nawrath L, Mueller V, Reuter S, Schmalfeldt B. Präliminäre Ergebnisse der Implementierung des “Enhanced Recovery After Surgery” (ERAS) Programms in der gynäkologischen Onkologie am Universitätsklinikum Hamburg - Eppendorf (UKE). Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- A Jaeger
- Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf
| | - L Woelber
- Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf
| | - K Prieske
- Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf
| | - C Trepte
- Klinik für Anästhesie, Universitätsklinikum Hamburg - Eppendorf
| | - L Nawrath
- Klinik für Anästhesie, Universitätsklinikum Hamburg - Eppendorf
| | - V Mueller
- Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf
| | - S Reuter
- Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf
| | - B Schmalfeldt
- Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf
| |
Collapse
|
11
|
Riecke K, Mueller V, Neunhöffer T, Weide R, Schmidt M, Park-Simon TW, Mundhenke C, Polasik A, Hesse T, Lübbe K, Laakmann E, Thill M, Fasching P, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Witzel I. Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry – comparison of three different prognostic scores. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- K Riecke
- Universitätklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie
| | - V Mueller
- Universitätklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie
| | | | - R Weide
- Institut für Versorgungsforschung in der Onkologie
| | | | | | | | | | - T Hesse
- Agaplesion Diakonieklinikum Rotenburg
| | - K Lübbe
- Diakovere Henriettenstift, Breast Center
| | - E Laakmann
- Universitätklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie
| | - M Thill
- Agaplesion Markus Krankenhaus
| | | | - C Denkert
- Institut für Pathologie UKGM – Universitätsklinikum Marburg
| | - T Fehm
- Universitätsklinikum Düsseldorf
| | | | - J Rey
- German Breast Group, GBG Forschungs GmbH
| | - S Loibl
- German Breast Group, GBG Forschungs GmbH
| | - I Witzel
- Universitätklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie
| |
Collapse
|
12
|
Mueller V, Paplomata E, Hamilton E, Zelnak A, Fehrenbacher L, Jakobsen E, Curtit E, Boyle F, Brix E, Brenner A, Ferrario C, Munoz-Mateu M, Arkenau T, Gelmon K, Cameron D, Curigliano G, DeBusk K, Ramos J, An X, Wardley A. 275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.377] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
13
|
Curigliano G, Murthy R, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz S, Cameron D, Borges V, Bedard P, Oliveira M, Jakobsen E, Bachelot T, Shachar S, Mueller V, Carey L, Loibl S, Feng W, Walker L, Winer E. 137O Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.03.238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
14
|
Paplomata E, Bachelot T, Mueller V, Murias C, Murthy R, Okines A, Wardley A, Walker L, Antunes De Melo e Oliveira A. A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz100.049] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Jank P, Loibl S, Fasching P, Karn T, Marmé F, Mueller V, Schem C, Stickeler E, Lederer B, Denkert C. Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz095.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Iacoi A, Brobeil A, Goette M, Enzensberger C, Mueller V, Axt-Fliedner R. Hydrops fetalis And Congenital Pulmonary Capillary Haemangiomatosis in a Premature Infant, A Case Report And Literature Review. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1660616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- A Iacoi
- Division of Prenatal Medicine, Dept. Obstetrics and Gynecology, Justus-Liebig-University Gießen, UKGM, Gießen
| | - A Brobeil
- Division of Pathology, Justus-Liebig-University, UKGM, Gießen
| | - M Goette
- Division of Prenatal Medicine, Dept. Obstetrics and Gynecology, Justus-Liebig-University Gießen, UKGM, Gießen
| | - C Enzensberger
- Division of Prenatal Medicine, Dept. Obstetrics and Gynecology, Justus-Liebig-University Gießen, UKGM, Gießen
| | - V Mueller
- Division of Prenatal Medicine, Dept. Obstetrics and Gynecology, Justus-Liebig-University Gießen, UKGM, Gießen
| | - R Axt-Fliedner
- Division of Prenatal Medicine, Dept. Obstetrics and Gynecology, Justus-Liebig-University Gießen, UKGM, Gießen
| |
Collapse
|
17
|
Huober J, Fasching PA, Taran FA, Volz B, Overkamp F, Kolberg HC, Hadji P, Tesch H, Haeberle L, Ettl J, Hartkopf AD, Lux MP, Lueftner D, Wallwiener M, Mueller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Janni W, Wallwiener D, Brucker SY, Schneeweiss A, Fehm TN. Abstract P3-11-07: Factors associated with first line chemotherapy use in patients with hormone receptor positive, HER2 negative metastatic breast cancer – data from the PRAEGNANT breast cancer registry. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-11-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
For breast cancer patients with metastases which are not life threatening national and international guidelines recommend the exhaustion of all antihormonal therapeutic options before recommending chemotherapy. In Germany up to now only everolimus was an additional option to overcome endocrine resistance. CDK4/6 inhibitors recently became available in Germany (Nov 2011). Aim of this analysis was the identification of predictors for a decision against an antihormonal treatment.
Methods
The PRAEGNANT metastatic breast cancer registry (NCT02338167) is a prospective registry for metastatic breast cancer patients. Besides biomarker research the description of real-world treatment data was one of the main study aims. This analysis was restricted to first line metastatic patients who were hormone receptor (HR) positive and HER2 negative. First, predictors were identified with a multiple logistic regression model. Then patients, who received chemo or not ,were compared with regard to overall survival using Cox regression analysis with the predictors for chemotherapy from above and additionally chemo status (yes/no)
Results
A total of 389 HR-positive and HER2-negative patients with detailed treatment information were included during the 1st line therapy into PRAEGNANT. Of those 173 (44.5%) received a chemotherapy, 190 an antihormone therapy (AHT) (48.8%), and 26 (6.7%) everolimus+AHT. In the multiple logistic regression model, older patients, lower graded tumors, bone only disease and previous adjuvant chemotherapy were associated with a lower rate of first line chemotherapies. BMI and number of concomitant diseases had no influence on the choice of first line metastatic therapy. In patients with visceral metastases 58.1% were treated with a 1st line chemo, while in patients with brain metastases or bone only metastases these numbers were 55.6% and 26.9%. Grading had an influence with patients having a G1, G2 and G3 tumor receiving 1st line chemo in 28.0%, 38.4% and 63.2% of the cases respectively. Patients who received chemo seemed to have a worse overall survival than patients who did not receive chemo (adjusted HR 1.58; 95% CI, 0.89 to 2.18). However, this result was not signifcant (p = 0.12). Overall survival was primarily influenced by ECOG and location of metastasis
Conclusion
The usage of chemotherapy can be predicted with age, metastasis pattern, grading and previous use of chemotherapy. However, we could not show that patients benefited from chemotherapy. On contrary, there was a tendency that patients treated with chemotherapy had poorer overall survival. Further studies with larger sample sizes are needed to confirm this claim.
Citation Format: Huober J, Fasching PA, Taran F-A, Volz B, Overkamp F, Kolberg HC, Hadji P, Tesch H, Haeberle L, Ettl J, Hartkopf AD, Lux MP, Lueftner D, Wallwiener M, Mueller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Janni W, Wallwiener D, Brucker SY, Schneeweiss A, Fehm TN. Factors associated with first line chemotherapy use in patients with hormone receptor positive, HER2 negative metastatic breast cancer – data from the PRAEGNANT breast cancer registry [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-11-07.
Collapse
Affiliation(s)
- J Huober
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - PA Fasching
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - F-A Taran
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - B Volz
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - F Overkamp
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - HC Kolberg
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - P Hadji
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - H Tesch
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - L Haeberle
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - J Ettl
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - AD Hartkopf
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - MP Lux
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - D Lueftner
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - M Wallwiener
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - V Mueller
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - MW Beckmann
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - E Belleville
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - P Wimberger
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - C Hielscher
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - M Geberth
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - N Fersis
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - W Abenhardt
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - C Kurbacher
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - R Wuerstlein
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - C Thomssen
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - M Untch
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - W Janni
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - D Wallwiener
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - SY Brucker
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - A Schneeweiss
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - TN Fehm
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| |
Collapse
|
18
|
Loibl S, Barinoff J, Seiler S, Decker T, Denkert C, Hardy-Bessard AC, Senkus-Konefka E, Cognetti F, Palmieri C, Gelmon K, Luebbe K, Furlanetto J, Mueller V, Mundhenke C, Schmidt M, von Minckwitz G, Uhlig M, Burchardi N, Thill M. Abstract OT3-05-04: A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-05-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Although endocrine therapy (ET) is recommended as first-line therapy for hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) up to 50% of patients receive chemotherapy in this setting. Meanwhile new targeted treatment options for combination with ET have been developed and endocrine-based therapy with the CDK4/6 inhibitor Palbociclib (P) improves the progression free survival (PFS) of ET alone by about 50%. So far, there is no data comparing chemotherapy with or without maintenance ET and ET in combination with P as first-line therapy. Patients included in clinical trials are often criticized not to mirror the general breast cancer population and every-day clinical practice due to rigid inclusion and exclusion criteria, limited number of treatment options, strict monitoring intervals and study assessments.
Methods:
PADMA trial is a so called low intervention trial with no rigid inclusion and exclusion criteria, and study assessments.Patients with first-line HR+/HER2- MBC who are candidate for mono-chemotherapy will be eligible to receive either P plus ET per label or mono-chemotherapy per investigator´s choice with or without maintenance ET (1:1 randomization). Primary objective is to compare the time-to-treatment failure (TTF) for patients randomized to receive the mono-chemotherapy treatment strategy versus those randomized to receive P and ET. TTF is defined as time from randomization to discontinuation of treatment due to disease progression, treatment toxicity, patient's preference, or death. Main secondary objectives are progression free survival, overall survival at 36 months, amongst other time to event endpoints as well as toxicity and compliance. All patients receive a specific mobile device (PADMA-Phone) and a validated wearable device (ActiWatch) in order to collect data regarding sleep and activity levels, patient well-being and health care utilization (number and duration of phone calls, and patient visits to investigator site) for assessment of daily monitoring treatment impact (DMTI).
Results:
Overall, 360 patients will be accrued to show an improved TTF for P in combination with ET compared to mono-chemotherapy of investigator´s choice with or without maintenance ET. Recruitment will start in QIII/2017 and is planned for approximately 18 months in 100 sites in Germany, Spain, Poland, Italy, France, UK and Canada.
Conclusions:
The aim of PADMA is to demonstrate that an endocrine-based strategy consisting of ET plus P is superior to a chemotherapy-based strategy as first-line therapy in women with HR+/HER2- MBC in a real world setting. Assessment of patient-reported outcome, health care utilization, and sleep and activity levels will deliver important information on the differences between endocrine-based and chemotherapy-based treatment.
Citation Format: Loibl S, Barinoff J, Seiler S, Decker T, Denkert C, Hardy-Bessard A-C, Senkus-Konefka E, Cognetti F, Palmieri C, Gelmon K, Luebbe K, Furlanetto J, Mueller V, Mundhenke C, Schmidt M, von Minckwitz G, Uhlig M, Burchardi N, Thill M. A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-05-04.
Collapse
Affiliation(s)
- S Loibl
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - J Barinoff
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - S Seiler
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - T Decker
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - C Denkert
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - A-C Hardy-Bessard
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - E Senkus-Konefka
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - F Cognetti
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - C Palmieri
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - K Gelmon
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - K Luebbe
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - J Furlanetto
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - V Mueller
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - C Mundhenke
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - M Schmidt
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - G von Minckwitz
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - M Uhlig
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - N Burchardi
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - M Thill
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| |
Collapse
|
19
|
Szeto C, Benz S, Nguyen A, Rübner M, Wallwiener D, Tesch H, Hadji P, Fehm TN, Janni W, Overkamp F, Lueftner D, Lux MP, Wallwiener M, Beckmann MW, Huebner H, Ettl J, Hartkopf AD, Mueller V, Taran FA, Belleville E, Schneeweiss A, Soon-Shiong P, Rabizadeh S, Fasching PA. Abstract P1-07-20: Developing prognostic indicators of poor outcomes in PRAEGNANT metastatic breast cancer cohort. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-07-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Despite novel, targeted therapies, metastatic breast cancer patients have an extremely unfavourable prognosis. Prognostic and predictive factors for patients with advanced breast cancer are not well understood. Molecular assessment of the patient and the tumor in the metastatic situation is not routinely performed despite advances in molecular precision medicine indicating great benefit to this patient group. Here we present early findings from the first 142 patients of a prospective molecular breast cancer registry with completed transcriptomic profiling.
Methods: The PRAEGNANT study proctocol (NCT02338767) is a molecular registry designed to provide an infrastructure for the real-time comprehensive analysis of tumor and patient molecular characteristics under study conditions. Formalin fixed paraffin embedded tumors have been used from this registry to identify molecular, transcriptomic predictors for overall survival (OS).
Known clinical correlates for OS (e.g. hormone-receptor status, age at diagnosis, and BMI) were analyzed by Cox proportional hazard ratios, and compared to transcriptomic markers of outcomes. Transcriptomes for all patient tumors were sequenced on the Illumina sequencing platform, and analyzed by RSEM to estimate transcripts per million (TPM) values for each gene isoform. Log-TPM values were used in established (PAM50) and novel (hierarchical clustering) expression-based subtyping of tumor samples. Expression-based subtypes were demonstrated to be strong prognostic indicators by Cox analysis. A Lasso regression machine learning algorithm was used to develop an expression-based predictive model of OS.
Results: Hormone receptor positivity (HR=0.7, p<0.006) and TNBC status (HR=1.4, p<0.01) were significantly associated with outcomes. PAM50 subtypes were also strong indicators of outcomes (e.g. Basal disease compared to Luminal-A subtype has HR=1.4, p<0.017). A novel expression-based high-risk cluster in this cohort was more indicative of poor prognosis than clinical variates or Basal-type, with a HR=2.7 (p<0.009) when compared to Luminal-A subtype. An expression-based survival prediction model achieved a concordance-index of 0.65 in an unseen validation cohort. Patients predicted as having the shortest survival times were in the high-risk cluster.
Conclusions: Here we demonstrate using molecular profiling to develop prognostic signatures that out-perform standard clinical correlates of poor outcomes, even in a small subset of the total cohort. As the PRAEGNANT cohort expands these prognostic tools will continue to improve and supplement physician knowledge to improve patient outcomes.
Citation Format: Szeto C, Benz S, Nguyen A, Rübner M, Wallwiener D, Tesch H, Hadji P, Fehm TN, Janni W, Overkamp F, Lueftner D, Lux MP, Wallwiener M, Beckmann MW, Huebner H, Ettl J, Hartkopf AD, Mueller V, Taran FA, Belleville E, Schneeweiss A, Soon-Shiong P, Rabizadeh S, Fasching PA. Developing prognostic indicators of poor outcomes in PRAEGNANT metastatic breast cancer cohort [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-07-20.
Collapse
Affiliation(s)
- C Szeto
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - S Benz
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - A Nguyen
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - M Rübner
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - D Wallwiener
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - H Tesch
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - P Hadji
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - TN Fehm
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - W Janni
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - F Overkamp
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - D Lueftner
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - MP Lux
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - M Wallwiener
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - MW Beckmann
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - H Huebner
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - J Ettl
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - AD Hartkopf
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - V Mueller
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - FA Taran
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - E Belleville
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - A Schneeweiss
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - P Soon-Shiong
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - S Rabizadeh
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - PA Fasching
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| |
Collapse
|
20
|
Romashova T, Polasik A, Friedl TWP, Rack B, Tzschaschel M, Fasching PA, Taran FA, Hartkopf A, Schneeweiss A, Mueller V, Bahriye A, Pantel K, Meier-Stiegen F, Wimberger P, Janni W, Fehm T, Huober J. Abstract OT1-03-05: The DETECT V-Study – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot1-03-05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Metastatic breast cancer (MBC) is usually an incurable disease and maintenance of quality of life (QoL) is one of the main aims of therapy. In patients with HER2-positive MBC taxane-based chemotherapy in combination with dual HER2 targeted therapy with trastuzumab and pertuzumab, has shown significantly increased progression free survival and overall survival. Adverse events are well-known side effects of any cytostatic treatment and can seriously impact the patients' QoL.
The synergistic combination of dual HER2-targeted therapy with trastuzumab and pertuzumab plus endocrine therapy might offer a better treatment option for these patients. Preclinical data and first clinical trial results suggest an additional benefit when a CDK4/6 inhibitor is added to the combination of endocrine therapy and anti HER2 treatment. DETECT V is a randomized phase III study comparing the safety and efficacy of trastuzumab plus pertuzumab in combination with either endocrine therapy or chemotherapy. In both treatment arms the CDK4/6 inhibitor ribociclib will be added.
Trial design and eligibility criteria: Patients are 1:1 randomized to receive dual HER2-targeted therapy with trastuzumab and pertuzumab combined with endocrine therapy and ribociclib or to chemotherapy with trastuzumab and pertuzumab followed by maintenance therapy with trastuzumab, pertuzumab, endocrine therapy and ribociclib when chemotherapy has stopped.
The sample size calculations are based on the assumption that the probability of having an adverse event as defined by the modified adverse event score for patients with HER2 positive metastatic breast cancer in the chemotherapy arm is 86.3%. Based on this assumption, a minimum of 121 patients per treatment arm is required to detect a 25% decreased risk of having an adverse event as defined by the modified adverse event score (i.e. a relative risk ratio of 0.75) for patients treated with dual HER2-targeted plus endocrine therapy and ribociclib as compared to patients treated with dual HER2-targeted plus chemotherapy with the combination of endocrine therapy and ribociclib as maintenance treatment (90% power, two-sided test, α = 0.05).
Specific aims: The primary objective of this study is to assess the tolerability of both treatment strategies, as assessed by the occurrence of AEs during the treatment period. Modified adverse event score was developed in order to better reflect the clinical, physiological and psychological impact of AEs on patients' QoL. Key secondary endpoint, besides the efficacy endpoints progression free survival (PFS) and overall survival, is to compare quality-adjusted survival (QAS), as measured using the quality-adjusted time without symptoms and toxicity (Q-TWiST) method, between both treatment arms.
The DETECT V trial comes along with a comprehensive translational program focusing on detection and phenotyping of circulating tumor cell (CTC)-and the assessment of marker expression on CTCs in order to calculate an endocrine responsiveness score.
Citation Format: Romashova T, Polasik A, Friedl TWP, Rack B, Tzschaschel M, Fasching PA, Taran F-A, Hartkopf A, Schneeweiss A, Mueller V, Bahriye A, Pantel K, Meier-Stiegen F, Wimberger P, Janni W, Fehm T, Huober J. The DETECT V-Study – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT1-03-05.
Collapse
Affiliation(s)
- T Romashova
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - A Polasik
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - TWP Friedl
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - B Rack
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - M Tzschaschel
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - PA Fasching
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - F-A Taran
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - A Hartkopf
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - A Schneeweiss
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - V Mueller
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - A Bahriye
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - K Pantel
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - F Meier-Stiegen
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - P Wimberger
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - W Janni
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - T Fehm
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - J Huober
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| |
Collapse
|
21
|
Wallwiener M, Nabieva N, Haeberle L, Taran FA, Hartkopf AD, Volz B, Overkamp F, Brandl AL, Kolberg HC, Hadji P, Tesch H, Ettl J, Lux MP, Lueftner D, Belleville E, Fasching PA, Janni W, Beckmann MW, Wimberger P, Hielscher C, Fehm T, Brucker SY, Wallwiener D, Schneeweiss A, Mueller V. Abstract P6-11-10: Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-11-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Improved progression-free survival is considered as treatment goal for patients with metastatic breast cancer (MBC) since it is assumed to delay or prevent deterioration of quality of life.Aim of our analysis was to examine the influence of disease progression on health-related quality of life (HRQoL).
Methods: The PRAEGNANT study comprises a real-life registry for patients with MBC. HRQoL was assessed with the EORTC-QLQ-C30 Version 3.0 questionnaire at study entry and every 3 months thereafter. The primary endpoint was minimally important deterioration (MID) in global HRQoL score by ≥ five points between baseline and any follow-up assessment. A logistic regression model was built with MID (yes/no) at a follow-up timepoint as outcome variable and several covariates as predictors.
Results: In total, 329 patients were included in this analysis, with disease progression in 63 patients. Concerning the primary study aim, progression status predicted MID of global HRQoL status in addition to the other covariates. The adjusted odds ratio for the effect of progression status on MID was 2.22 (95% CI: 1.04 – 4.73). Comparisons of mean differences of QoL domains/scales yielded no differences.
Conclusions: We provide evidence that disease progression in patients with metastatic breast cancer in a real-world registry has a significant negative impact on HRQoL as measured by MID of HRQoL. This study emphasizes the relevance of avoiding progression and prolonging PFS to maintain QoL.
Citation Format: Wallwiener M, Nabieva N, Haeberle L, Taran FA, Hartkopf AD, Volz B, Overkamp F, Brandl AL, Kolberg H-C, Hadji P, Tesch H, Ettl J, Lux MP, Lueftner D, Belleville E, Fasching PA, Janni W, Beckmann MW, Wimberger P, Hielscher C, Fehm T, Brucker SY, Wallwiener D, Schneeweiss A, Mueller V. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-11-10.
Collapse
Affiliation(s)
- M Wallwiener
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - N Nabieva
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - L Haeberle
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - FA Taran
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - AD Hartkopf
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - B Volz
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - F Overkamp
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - AL Brandl
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - H-C Kolberg
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - P Hadji
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - H Tesch
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - J Ettl
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - MP Lux
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - D Lueftner
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - E Belleville
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - PA Fasching
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - W Janni
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - MW Beckmann
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - P Wimberger
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - C Hielscher
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - T Fehm
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - SY Brucker
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - D Wallwiener
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - A Schneeweiss
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - V Mueller
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| |
Collapse
|
22
|
Tzschaschel MLJ, Rack B, Andergassen U, Friedl TWP, Schneeweiss A, Mueller V, Tanja F, Pantel K, Gade J, Lorenz R, Rezai M, Tesch H, Soeling U, Polasik A, Alunni-Fabbroni M, Trapp EK, Mahner S, Schindlbeck C, Lichtenegger W, Beckmann MW, Fasching PA, Janni W. Abstract P1-01-03: Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients – Results from the adjuvant SUCCESS A trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-01-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The presence of circulating tumor cells (CTCs) before chemotherapy is known to be associated with reduced disease free survival (DFS) and overall survival (OS) in early breast cancer (EBC). In addition, recent findings suggest that CTCs persisting after adjuvant chemotherapy indicate poor prognosis. In an explorative analysis of the SUCCESS A trial, we evaluated the prognostic relevance of changes in CTC counts during the course of adjuvant chemotherapy across molecular subtypes to assess whether the prognostic role of persisting CTCs varies according to tumor biology.
Methods: The SUCCESS A trial is a phase III study, where patients with high-risk EBC (stage pN1-3 or pT2-4 or grade 3 or age ≤ 35 or hormone-receptor negative) were randomized to adjuvant chemotherapy with 3 cycles of epirubicin-fluorouracil-cyclophosphamide followed by either 3 cycles of docetaxel or 3 cycles of gemcitabine-docetaxel. CTC enumeration was performed before and after chemotherapy using the FDA-approved CellSearch® System (Janssen Diagnostics, LLC), and CTC positivity was defined as ≥ 1 CTC in 23 ml blood. Molecular subtypes were defined as luminal A like (hormone-receptor positive, grading 1 or 2), luminal B like (hormone-receptor positive, grading 3), triple-negative or HER2-positive. Patient outcome in terms of DFS and OS was analyzed using univariate log-rank tests and Cox regression models (median follow-up time 65.2 months).
Results: Data on both molecular subtypes and CTC status before and after chemotherapy were available for 1485 (39.6%) of 3754 patients randomized. This cohort contained 577 (38.9%) luminal A like, 236 (15.9%) luminal B like, 379 (25.5%) HER2-positive and 293 (19.7%) triple negative tumors. Overall, 917 (61.8%) patients were CTC negative before and after chemotherapy (neg/neg), 260 (17.5%) patients had a negative CTC status before and a positive CTC status after chemotherapy (neg/pos), 229 (15.4%) patients converted from positive to negative CTC status (pos/neg), and 79 (5.3%) patients were positive for CTCs at both time points (pos/pos). There were significant differences in DFS and OS among these four groups in patients with luminal A like tumors (log rank test, both p < 0.003) and patients with luminal B like tumors (log rank test, both p < 0.001). In both patients with luminal A like or luminal B like tumors, persistently CTC positive patients had the worst outcome (relative to persistently CTC-negative patients) in terms of DFS and OS. In contrast to luminal-like tumors, no significant differences with regard to DFS or OS were found among the four groups (neg/neg, neg/pos, pos/neg, pos/pos) in patients with HER2-positive or triple-negative tumors (log rank test, all p > 0.13).
Conclusion: The presence of CTCs both before and after adjuvant chemotherapy was associated with poor survival in luminal A like and luminal B like tumors, but not in HER2-positive or triple-negative tumors. Further research is needed to evaluate the effect of chemotherapy on CTC prevalence in different molecular subtypes of EBC.
Citation Format: Tzschaschel MLJ, Rack B, Andergassen U, Friedl TWP, Schneeweiss A, Mueller V, Tanja F, Pantel K, Gade J, Lorenz R, Rezai M, Tesch H, Soeling U, Polasik A, Alunni-Fabbroni M, Trapp EK, Mahner S, Schindlbeck C, Lichtenegger W, Beckmann MW, Fasching PA, Janni W. Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients – Results from the adjuvant SUCCESS A trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-01-03.
Collapse
Affiliation(s)
- MLJ Tzschaschel
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - B Rack
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - U Andergassen
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - TWP Friedl
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - A Schneeweiss
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - V Mueller
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - F Tanja
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - K Pantel
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - J Gade
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - R Lorenz
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - M Rezai
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - H Tesch
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - U Soeling
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - A Polasik
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - M Alunni-Fabbroni
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - EK Trapp
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - S Mahner
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - C Schindlbeck
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - W Lichtenegger
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - MW Beckmann
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - PA Fasching
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| | - W Janni
- Ludwig Maximilians Universitaet Muenchen Klinik und Poliklinik fuer Frauenheilkunde und Gerburtshilfe, Munich, Germany; University Hospital Ulm, Ulm, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diakoniekrankenhaus Friederikenstift, Hannover, Germany; Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche, Braunschweig, Germany; Luisenkrankenhaus Duesseldorf, Duesseldorf, Germany; Onkologische Gemeinschaftspraxis am Betahnien-Krankenhaus, Frankfurt, Germany; Gemeinschaftspraxis Siehl und Soeling, Cassel, Germany; Clinical Center Traunstein, Traunstein, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Hospital Erlangen, Friedrich-Alexander, Erlangen, Germany
| |
Collapse
|
23
|
Mueller V, Jakob A, Aktas B, Pott D, Grafe A, Jungberg P, Maerz W, Fett W, Bruch HR, Klare P, Boller E, Hoefflin S, Schneeweiss A. Abstract P6-13-02: Efficacy of first-line bevacizumab (BEV)-containing therapy for poor-prognosis advanced breast cancer (aBC): Subgroup analyses of the German AVANTI observational study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-13-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The multicenter AVANTI observational study is evaluating the safety and effectiveness of EU-approved BEV-containing regimens (BEV + paclitaxel [PAC] or BEV + capecitabine [CAP]) as first-line therapy for HER2-negative aBC in German routine oncology practice.
Methods: Eligible patients (pts) had received no prior chemotherapy (CT) for aBC and had no BEV contraindications. CT schedule, diagnostics, and frequency of follow-up visits are at the physician's discretion. Data are collected for 1 year after starting BEV, with 6-monthly follow-up for 1.5 years thereafter. We explored treatment outcomes in pts with triple-negative aBC (TNBC), pts considered at high risk according to a simple prognostic index for OS in BEV-treated pts [Llombart, 2014], and subgroups defined by timing of BEV+CT initiation.
Results: Between Oct 2009 and Feb 2015, 2168 pts treated at 331 centers received BEV+PAC (n=1774) or BEV+CAP (n=394). Of these, 445 (21%) had TNBC and 306 (14%) met the high-risk criteria. Within the hormone receptor-positive (HR+) subgroup, pts receiving endocrine therapy (ET) before BEV+CT were older than pts starting BEV+CT immediately (median age 65 vs 60 years, respectively) and included a smaller proportion with ECOG performance status 0 (39% vs 47%), visceral metastases (70% vs 77%), or prior (neo)adjuvant CT exposure (46% vs 57%). In all subgroups, median BEV treatment duration was longer than median CT duration. At the data cutoff for this interim analysis (Mar 1, 2015), median duration of observation was 10.8 (range <0.1–47.5) months. The table shows treatment exposure and efficacy overall and in selected subgroups.
table 1 All pts (n=2168)TNBC (n=445)aHR+ with immediate BEV+CT (n=1260)a,bHR+ with ET before BEV+CT (n=309)a,bHigh riskc (n=306)bBEV+PAC, n (%)1774 (82)352 (79)b1062 (84)238 (77)229 (75)Treated until PD, n (%)b,d640 (30)180 (40)314 (25)104 (34)125 (41)BEV+CT until PD449 (21)143 (32)210 (17)61 (20)99 (32)Single-agent BEV until PD191 (9)37 (8)104 (8)43 (14)26 (8)Median BEV duration, months (95% CI)5.9 (5.6–6.3)5.1 (4.9–5.6)6.4 (5.9–7.0)5.6 (5.1–6.5)5.1 (4.6–5.6)Median CT duration, months4.6 (4.4–4.9)3.9 (3.5–4.2)4.9 (4.6–5.1)4.6 (4.2–5.1)3.9 (3.3–4.4)No. of PFS events/pts (%)e1238/2154 (57)302/441 (68)667/1255 (53)187/307 (61)210/306 (69)Median PFS, months (95% CI)10.1 (9.7–10.7)7.2 (6.2–8.0)11.5 (10.8–12.3)9.0 (8.3–10.0)6.4 (5.9–7.4)a154 pts could not be classified as TNBC or HR+ because of missing HR status information. bPost hoc analysis. c≥3 of the 5 risk factors (disease-free interval ≤24 months; ECOG performance status ≥2; liver metastases and/or ≥3 metastatic organ sites; TNBC; prior (neo)adjuvant anthracycline and/or taxane). dData available only in pts with documented end of treatment. ePFS data missing in 14 pts.
Conclusions: Interim results from this large observational study indicate that first-line BEV+CT is an effective therapy in all risk subgroups of a general population of pts with HER2-negative aBC treated in routine oncology practice, including pts with a particularly poor prognosis. Results of these exploratory subgroup analyses suggest that BEV+CT could be considered irrespective of HR status.
Citation Format: Mueller V, Jakob A, Aktas B, Pott D, Grafe A, Jungberg P, Maerz W, Fett W, Bruch H-R, Klare P, Boller E, Hoefflin S, Schneeweiss A. Efficacy of first-line bevacizumab (BEV)-containing therapy for poor-prognosis advanced breast cancer (aBC): Subgroup analyses of the German AVANTI observational study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-13-02.
Collapse
Affiliation(s)
- V Mueller
- Universitaetsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynaekologie, Hamburg, Germany; Ortenau-Klinikum, Offenburg, Germany; Universitaetsklinikum Essen, Essen, Germany; Schwerpunktpraxis Haematologie und Onkologie, Bottrop, Germany; MVZ Nordhausen gGmbH, Praxis Dr. Grafe/Brustzentrum der Frauenklinik, Suedharz- Klinikum Nordhausen gGmbH, Nordhausen, Germany; Frauenarztpraxis Dr. Jungberg, Chemnitz, Germany; Onkologie Klinikum Kulmbach, Kulmbach, Germany; Onkologische Praxis, Wuppertal, Germany; Schwerpunktpraxis Bonn, Bonn, Germany; Brustzentrum Berlin, Berlin, Germany; iOMEDICO Clinical Research Organisation, Freiburg, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Universitaets-Klinikum Heidelberg, Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - A Jakob
- Universitaetsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynaekologie, Hamburg, Germany; Ortenau-Klinikum, Offenburg, Germany; Universitaetsklinikum Essen, Essen, Germany; Schwerpunktpraxis Haematologie und Onkologie, Bottrop, Germany; MVZ Nordhausen gGmbH, Praxis Dr. Grafe/Brustzentrum der Frauenklinik, Suedharz- Klinikum Nordhausen gGmbH, Nordhausen, Germany; Frauenarztpraxis Dr. Jungberg, Chemnitz, Germany; Onkologie Klinikum Kulmbach, Kulmbach, Germany; Onkologische Praxis, Wuppertal, Germany; Schwerpunktpraxis Bonn, Bonn, Germany; Brustzentrum Berlin, Berlin, Germany; iOMEDICO Clinical Research Organisation, Freiburg, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Universitaets-Klinikum Heidelberg, Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - B Aktas
- Universitaetsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynaekologie, Hamburg, Germany; Ortenau-Klinikum, Offenburg, Germany; Universitaetsklinikum Essen, Essen, Germany; Schwerpunktpraxis Haematologie und Onkologie, Bottrop, Germany; MVZ Nordhausen gGmbH, Praxis Dr. Grafe/Brustzentrum der Frauenklinik, Suedharz- Klinikum Nordhausen gGmbH, Nordhausen, Germany; Frauenarztpraxis Dr. Jungberg, Chemnitz, Germany; Onkologie Klinikum Kulmbach, Kulmbach, Germany; Onkologische Praxis, Wuppertal, Germany; Schwerpunktpraxis Bonn, Bonn, Germany; Brustzentrum Berlin, Berlin, Germany; iOMEDICO Clinical Research Organisation, Freiburg, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Universitaets-Klinikum Heidelberg, Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - D Pott
- Universitaetsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynaekologie, Hamburg, Germany; Ortenau-Klinikum, Offenburg, Germany; Universitaetsklinikum Essen, Essen, Germany; Schwerpunktpraxis Haematologie und Onkologie, Bottrop, Germany; MVZ Nordhausen gGmbH, Praxis Dr. Grafe/Brustzentrum der Frauenklinik, Suedharz- Klinikum Nordhausen gGmbH, Nordhausen, Germany; Frauenarztpraxis Dr. Jungberg, Chemnitz, Germany; Onkologie Klinikum Kulmbach, Kulmbach, Germany; Onkologische Praxis, Wuppertal, Germany; Schwerpunktpraxis Bonn, Bonn, Germany; Brustzentrum Berlin, Berlin, Germany; iOMEDICO Clinical Research Organisation, Freiburg, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Universitaets-Klinikum Heidelberg, Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - A Grafe
- Universitaetsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynaekologie, Hamburg, Germany; Ortenau-Klinikum, Offenburg, Germany; Universitaetsklinikum Essen, Essen, Germany; Schwerpunktpraxis Haematologie und Onkologie, Bottrop, Germany; MVZ Nordhausen gGmbH, Praxis Dr. Grafe/Brustzentrum der Frauenklinik, Suedharz- Klinikum Nordhausen gGmbH, Nordhausen, Germany; Frauenarztpraxis Dr. Jungberg, Chemnitz, Germany; Onkologie Klinikum Kulmbach, Kulmbach, Germany; Onkologische Praxis, Wuppertal, Germany; Schwerpunktpraxis Bonn, Bonn, Germany; Brustzentrum Berlin, Berlin, Germany; iOMEDICO Clinical Research Organisation, Freiburg, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Universitaets-Klinikum Heidelberg, Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - P Jungberg
- Universitaetsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynaekologie, Hamburg, Germany; Ortenau-Klinikum, Offenburg, Germany; Universitaetsklinikum Essen, Essen, Germany; Schwerpunktpraxis Haematologie und Onkologie, Bottrop, Germany; MVZ Nordhausen gGmbH, Praxis Dr. Grafe/Brustzentrum der Frauenklinik, Suedharz- Klinikum Nordhausen gGmbH, Nordhausen, Germany; Frauenarztpraxis Dr. Jungberg, Chemnitz, Germany; Onkologie Klinikum Kulmbach, Kulmbach, Germany; Onkologische Praxis, Wuppertal, Germany; Schwerpunktpraxis Bonn, Bonn, Germany; Brustzentrum Berlin, Berlin, Germany; iOMEDICO Clinical Research Organisation, Freiburg, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Universitaets-Klinikum Heidelberg, Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - W Maerz
- Universitaetsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynaekologie, Hamburg, Germany; Ortenau-Klinikum, Offenburg, Germany; Universitaetsklinikum Essen, Essen, Germany; Schwerpunktpraxis Haematologie und Onkologie, Bottrop, Germany; MVZ Nordhausen gGmbH, Praxis Dr. Grafe/Brustzentrum der Frauenklinik, Suedharz- Klinikum Nordhausen gGmbH, Nordhausen, Germany; Frauenarztpraxis Dr. Jungberg, Chemnitz, Germany; Onkologie Klinikum Kulmbach, Kulmbach, Germany; Onkologische Praxis, Wuppertal, Germany; Schwerpunktpraxis Bonn, Bonn, Germany; Brustzentrum Berlin, Berlin, Germany; iOMEDICO Clinical Research Organisation, Freiburg, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Universitaets-Klinikum Heidelberg, Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - W Fett
- Universitaetsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynaekologie, Hamburg, Germany; Ortenau-Klinikum, Offenburg, Germany; Universitaetsklinikum Essen, Essen, Germany; Schwerpunktpraxis Haematologie und Onkologie, Bottrop, Germany; MVZ Nordhausen gGmbH, Praxis Dr. Grafe/Brustzentrum der Frauenklinik, Suedharz- Klinikum Nordhausen gGmbH, Nordhausen, Germany; Frauenarztpraxis Dr. Jungberg, Chemnitz, Germany; Onkologie Klinikum Kulmbach, Kulmbach, Germany; Onkologische Praxis, Wuppertal, Germany; Schwerpunktpraxis Bonn, Bonn, Germany; Brustzentrum Berlin, Berlin, Germany; iOMEDICO Clinical Research Organisation, Freiburg, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Universitaets-Klinikum Heidelberg, Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - H-R Bruch
- Universitaetsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynaekologie, Hamburg, Germany; Ortenau-Klinikum, Offenburg, Germany; Universitaetsklinikum Essen, Essen, Germany; Schwerpunktpraxis Haematologie und Onkologie, Bottrop, Germany; MVZ Nordhausen gGmbH, Praxis Dr. Grafe/Brustzentrum der Frauenklinik, Suedharz- Klinikum Nordhausen gGmbH, Nordhausen, Germany; Frauenarztpraxis Dr. Jungberg, Chemnitz, Germany; Onkologie Klinikum Kulmbach, Kulmbach, Germany; Onkologische Praxis, Wuppertal, Germany; Schwerpunktpraxis Bonn, Bonn, Germany; Brustzentrum Berlin, Berlin, Germany; iOMEDICO Clinical Research Organisation, Freiburg, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Universitaets-Klinikum Heidelberg, Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - P Klare
- Universitaetsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynaekologie, Hamburg, Germany; Ortenau-Klinikum, Offenburg, Germany; Universitaetsklinikum Essen, Essen, Germany; Schwerpunktpraxis Haematologie und Onkologie, Bottrop, Germany; MVZ Nordhausen gGmbH, Praxis Dr. Grafe/Brustzentrum der Frauenklinik, Suedharz- Klinikum Nordhausen gGmbH, Nordhausen, Germany; Frauenarztpraxis Dr. Jungberg, Chemnitz, Germany; Onkologie Klinikum Kulmbach, Kulmbach, Germany; Onkologische Praxis, Wuppertal, Germany; Schwerpunktpraxis Bonn, Bonn, Germany; Brustzentrum Berlin, Berlin, Germany; iOMEDICO Clinical Research Organisation, Freiburg, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Universitaets-Klinikum Heidelberg, Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - E Boller
- Universitaetsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynaekologie, Hamburg, Germany; Ortenau-Klinikum, Offenburg, Germany; Universitaetsklinikum Essen, Essen, Germany; Schwerpunktpraxis Haematologie und Onkologie, Bottrop, Germany; MVZ Nordhausen gGmbH, Praxis Dr. Grafe/Brustzentrum der Frauenklinik, Suedharz- Klinikum Nordhausen gGmbH, Nordhausen, Germany; Frauenarztpraxis Dr. Jungberg, Chemnitz, Germany; Onkologie Klinikum Kulmbach, Kulmbach, Germany; Onkologische Praxis, Wuppertal, Germany; Schwerpunktpraxis Bonn, Bonn, Germany; Brustzentrum Berlin, Berlin, Germany; iOMEDICO Clinical Research Organisation, Freiburg, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Universitaets-Klinikum Heidelberg, Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - S Hoefflin
- Universitaetsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynaekologie, Hamburg, Germany; Ortenau-Klinikum, Offenburg, Germany; Universitaetsklinikum Essen, Essen, Germany; Schwerpunktpraxis Haematologie und Onkologie, Bottrop, Germany; MVZ Nordhausen gGmbH, Praxis Dr. Grafe/Brustzentrum der Frauenklinik, Suedharz- Klinikum Nordhausen gGmbH, Nordhausen, Germany; Frauenarztpraxis Dr. Jungberg, Chemnitz, Germany; Onkologie Klinikum Kulmbach, Kulmbach, Germany; Onkologische Praxis, Wuppertal, Germany; Schwerpunktpraxis Bonn, Bonn, Germany; Brustzentrum Berlin, Berlin, Germany; iOMEDICO Clinical Research Organisation, Freiburg, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Universitaets-Klinikum Heidelberg, Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - A Schneeweiss
- Universitaetsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynaekologie, Hamburg, Germany; Ortenau-Klinikum, Offenburg, Germany; Universitaetsklinikum Essen, Essen, Germany; Schwerpunktpraxis Haematologie und Onkologie, Bottrop, Germany; MVZ Nordhausen gGmbH, Praxis Dr. Grafe/Brustzentrum der Frauenklinik, Suedharz- Klinikum Nordhausen gGmbH, Nordhausen, Germany; Frauenarztpraxis Dr. Jungberg, Chemnitz, Germany; Onkologie Klinikum Kulmbach, Kulmbach, Germany; Onkologische Praxis, Wuppertal, Germany; Schwerpunktpraxis Bonn, Bonn, Germany; Brustzentrum Berlin, Berlin, Germany; iOMEDICO Clinical Research Organisation, Freiburg, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Universitaets-Klinikum Heidelberg, Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| |
Collapse
|
24
|
Prieske K, Haeringer N, Grimm D, Trillsch F, Eulenburg C, Burandt E, Schmalfeldt B, Mahner S, Mueller V, Woelber L. Patterns of distant metastases in vulvar cancer. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
25
|
Mueller V, Dank M, de Ducla S, Mitchell L, Schneeweiss A. Real-world effectiveness and safety of first-line bevacizumab (BEV) + paclitaxel (PAC) in >2000 patients (pts) with HER2-negative metastatic breast cancer (mBC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw365.16] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
26
|
Fasching PA, Wallwiener M, Lux MP, Mueller V, Schneeweiss A, Tesch H, Brucker SY, Haeberle L, Spall T, Belleville E, Lück HJ. Abstract OT3-02-09: Seraphina – Safety efficacy and patient reported outcomes of advanced breast cancer patients: Therapy management with NAB-paclitaxel in daily routine. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-ot3-02-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND
Treatment of patients with advanced breast cancer (ABC) has evolved significantly. Nevertheless, further improvement in ABC treatment is a high medical need. Besides the prolongation of progression free survival (PFS) and overall survival (OS) the major objective of new therapeutic approaches is the enhancement of quality of life (QoL). A recent advance for the treatment of ABC was the development of the cremophor-free albumin-bound paclitaxel, nab-Paclitaxel.
SPECIFIC AIMS/TRIAL DESIGN
The aim of this non-interventional study is the analysis of efficacy and safety data of ABC patients within routine treatment with nab-Paclitaxel. A key focus will be the assessment of patient reported outcomes (PRO), health economic aspects and the influence of breast cancer patient characteristics on prognosis, adverse event frequencies, PRO and therapy decision making. Patients with ABC, who experienced failure of first-line treatment for metastatic disease and for whom standard anthracycline-containing therapy is not indicated, will be followed up under real-life conditions. Sixty sites, equally distributed with regard to their organizational structure (hospital and office based) and medical disciplines (gyneco-oncologists and medical oncologists) will document 1,200 patients. The primary objective is the assessment of PFS under real-life conditions. Secondary objectives include the assessment of overall and breast cancer specific survival, the influence of age on prognosis and QoL, as well as the incidence of (serious) adverse events (AE). PRO including FACT-B, FACT-Taxane, and nab-Paclitaxel treatment specific questions will be collected in a web based application and compared to paper based reporting. Furthermore, biomaterials will be collected to allow translational research projects.
ELIGIBILITY CRITERIA:
Adult women (>18 years) with ABC and treated with nab-Paclitaxel.
STATISTICAL METHODS/TARGET ACCRUAL:
In Germany nab-Paclitaxel is indicated for patients with metastatic breast cancer after failure of a previous therapy in ABC. In this therapeutic setting several studies have shown high efficacy and acceptable toxicity. However, populations within clinical trials are selected and may be different from the general patient population in clinical practice. Therefore this study aims at the capture of PFS, PRO and AE in the general population for which nab-Paclitaxel is used in clinical practice. Nab-Paclitaxel treatment will be documented over a period of up to 6 months, followed by a 30 months progression/ survival follow-up. Target accrual is 1,200 patients. We assume that at most 10% are lost to follow-up before the median survival time is reached. Kaplan-Meier curves will be calculated, especially the median survival time with 95% confidence interval.
Citation Format: Fasching PA, Wallwiener M, Lux MP, Mueller V, Schneeweiss A, Tesch H, Brucker SY, Haeberle L, Spall T, Belleville E, Lück H-J. Seraphina – Safety efficacy and patient reported outcomes of advanced breast cancer patients: Therapy management with NAB-paclitaxel in daily routine. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT3-02-09.
Collapse
Affiliation(s)
- PA Fasching
- University Hospital of Erlangen, Erlangen, Germany; University Hospital of Heidelberg, Heidelberg, Germany; University Hospital of Hamburg-Eppendorf, Hamburg, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Oncology Bethanien, Frankfurt/Main, Germany; University Hospital of Tuebingen, Tuebingen, Germany; ClinSol GmbH&Co KG, Wuerzburg, Germany; GOPH, Hannover, Germany
| | - M Wallwiener
- University Hospital of Erlangen, Erlangen, Germany; University Hospital of Heidelberg, Heidelberg, Germany; University Hospital of Hamburg-Eppendorf, Hamburg, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Oncology Bethanien, Frankfurt/Main, Germany; University Hospital of Tuebingen, Tuebingen, Germany; ClinSol GmbH&Co KG, Wuerzburg, Germany; GOPH, Hannover, Germany
| | - MP Lux
- University Hospital of Erlangen, Erlangen, Germany; University Hospital of Heidelberg, Heidelberg, Germany; University Hospital of Hamburg-Eppendorf, Hamburg, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Oncology Bethanien, Frankfurt/Main, Germany; University Hospital of Tuebingen, Tuebingen, Germany; ClinSol GmbH&Co KG, Wuerzburg, Germany; GOPH, Hannover, Germany
| | - V Mueller
- University Hospital of Erlangen, Erlangen, Germany; University Hospital of Heidelberg, Heidelberg, Germany; University Hospital of Hamburg-Eppendorf, Hamburg, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Oncology Bethanien, Frankfurt/Main, Germany; University Hospital of Tuebingen, Tuebingen, Germany; ClinSol GmbH&Co KG, Wuerzburg, Germany; GOPH, Hannover, Germany
| | - A Schneeweiss
- University Hospital of Erlangen, Erlangen, Germany; University Hospital of Heidelberg, Heidelberg, Germany; University Hospital of Hamburg-Eppendorf, Hamburg, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Oncology Bethanien, Frankfurt/Main, Germany; University Hospital of Tuebingen, Tuebingen, Germany; ClinSol GmbH&Co KG, Wuerzburg, Germany; GOPH, Hannover, Germany
| | - H Tesch
- University Hospital of Erlangen, Erlangen, Germany; University Hospital of Heidelberg, Heidelberg, Germany; University Hospital of Hamburg-Eppendorf, Hamburg, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Oncology Bethanien, Frankfurt/Main, Germany; University Hospital of Tuebingen, Tuebingen, Germany; ClinSol GmbH&Co KG, Wuerzburg, Germany; GOPH, Hannover, Germany
| | - SY Brucker
- University Hospital of Erlangen, Erlangen, Germany; University Hospital of Heidelberg, Heidelberg, Germany; University Hospital of Hamburg-Eppendorf, Hamburg, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Oncology Bethanien, Frankfurt/Main, Germany; University Hospital of Tuebingen, Tuebingen, Germany; ClinSol GmbH&Co KG, Wuerzburg, Germany; GOPH, Hannover, Germany
| | - L Haeberle
- University Hospital of Erlangen, Erlangen, Germany; University Hospital of Heidelberg, Heidelberg, Germany; University Hospital of Hamburg-Eppendorf, Hamburg, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Oncology Bethanien, Frankfurt/Main, Germany; University Hospital of Tuebingen, Tuebingen, Germany; ClinSol GmbH&Co KG, Wuerzburg, Germany; GOPH, Hannover, Germany
| | - T Spall
- University Hospital of Erlangen, Erlangen, Germany; University Hospital of Heidelberg, Heidelberg, Germany; University Hospital of Hamburg-Eppendorf, Hamburg, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Oncology Bethanien, Frankfurt/Main, Germany; University Hospital of Tuebingen, Tuebingen, Germany; ClinSol GmbH&Co KG, Wuerzburg, Germany; GOPH, Hannover, Germany
| | - E Belleville
- University Hospital of Erlangen, Erlangen, Germany; University Hospital of Heidelberg, Heidelberg, Germany; University Hospital of Hamburg-Eppendorf, Hamburg, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Oncology Bethanien, Frankfurt/Main, Germany; University Hospital of Tuebingen, Tuebingen, Germany; ClinSol GmbH&Co KG, Wuerzburg, Germany; GOPH, Hannover, Germany
| | - H-J Lück
- University Hospital of Erlangen, Erlangen, Germany; University Hospital of Heidelberg, Heidelberg, Germany; University Hospital of Hamburg-Eppendorf, Hamburg, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Oncology Bethanien, Frankfurt/Main, Germany; University Hospital of Tuebingen, Tuebingen, Germany; ClinSol GmbH&Co KG, Wuerzburg, Germany; GOPH, Hannover, Germany
| |
Collapse
|
27
|
Witzel I, Loibl S, Laakmann E, Augustin D, Flock F, Dohmen HH, Durmus G, Frank M, Hesse T, Ignatov A, Kühn T, Neunhöffer T, Park-Simon TW, Schmidt M, Stefek A, Weide R, Würschmidt F, Fehm T, Moebus V, von Minckwitz G, Burchardi N, Mueller V. Abstract P6-17-08: Brain metastases in breast cancer network Germany (BMBC, GBG 79): First analysis of 548 patients from the multicenter registry. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-17-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The incidence of brain metastases (BM) in breast cancer patients is rising and has become a major clinical challenge. So far, limited therapeutic options and insights into the biology of BM exist since only a few studies analyzed exclusively data of breast cancer patients. In order to improve this situation, our multicenter registry was initiated in 2014: Brain Metastases in Breast Cancer Network Germany (BMBC, GBG79).
Materials and Methods: Patients with BM diagnosed since 2000, a history of breast cancer and no history of other malignant or neurologic disease can be included. Registration is allowed retrospectively as well as prospectively into a web–based database ("MedCodes"). Characteristics of the primary tumor, metastatic disease and BM as well as treatment details are documented. For this first analysis, 548 patients from 39 German centers were included.
Results: Median age at first diagnosis of BM was 55 years (25 – 90 years). 43% of patients (233/548) were HER2 positive, 19% (n=105) were triple–negative and 25% (n= 138) had luminal primary tumors indicating a selection of patients with specific tumor biology who develop BM. 54 % of the patients (n=267) had up to three BM whereas 45% (n=223) had more than three BM. 19% of patients (n=106) had BM without evidence of extracranial disease. 27% of the patients (n=146) underwent surgery of the BM. Of these patients, 61% (n= 89) were treated with whole brain radiotherapy and 16% (n=23) with stereotactic radiotherapy. In patients without surgery (n=397), 73% (n=289) received whole brain radiotherapy and 7% (n=28) stereotactic radiotherapy.
Median time from diagnosis of primary breast cancer to BM was 38.5 month for the entire cohort (CI95% 35.4 – 43.3). The time from first diagnosis to BM was shorter for triple–negative patients (20.9 month, CI95% 15.5 – 25.9) compared with patients with HER2–positive (37.0 month, CI95% 30.5 – 42.0) or luminal tumors (48.3 month, CI95% 38.2 – 54.0) (p<0.001). Median time from first diagnosis of BM to death in the entire cohort was 6.1 months (CI95%: 5.2 – 7.3). One year survival rate from diagnosis of BM was 32.2 % (CI95%: 2.2 – 67.8). Regarding tumor subtypes, HER2–positive patients had the longest median survival with 9.4 months (CI95%: 7.1 – 13.4) compared with 6 months (CI95%: 4.0 – 7.3) for luminal primary tumors and 3.2 months (CI95%: 2.1 – 4.6) for triple–negative patients (p<0.001). HER2 positive patients receiving HER2–directed therapy after the diagnosis of BM lived longer than those without (median 9.6 vs. 5.5 months, p=0.029). Regarding the number of BM, no difference in survival was observed between one, two or three BM (median survival of 7.8 months). However, survival was shorter in those patients with more than three BM (5.2 months; p=0.007).
Conclusion: This is so far the largest analysis of breast cancer patients with BM treated in Germany. In this cohort, triple–negative subtype or more than three BM were associated with shorter survival from the diagnosis of BM. HER2 positive patients with no HER2 directed therapy after the diagnosis of BM showed a shorter survival. The recruitment of the registry is ongoing and we aim to include more than 1000 patients by the end of 2015.
Citation Format: Witzel I, Loibl S, Laakmann E, Augustin D, Flock F, Dohmen H-H, Durmus G, Frank M, Hesse T, Ignatov A, Kühn T, Neunhöffer T, Park-Simon T-W, Schmidt M, Stefek A, Weide R, Würschmidt F, Fehm T, Moebus V, von Minckwitz G, Burchardi N, Mueller V. Brain metastases in breast cancer network Germany (BMBC, GBG 79): First analysis of 548 patients from the multicenter registry. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-17-08.
Collapse
Affiliation(s)
- I Witzel
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - S Loibl
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - E Laakmann
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - D Augustin
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - F Flock
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - H-H Dohmen
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - G Durmus
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - M Frank
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - T Hesse
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - A Ignatov
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - T Kühn
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - T Neunhöffer
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - T-W Park-Simon
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - M Schmidt
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - A Stefek
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - R Weide
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - F Würschmidt
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - T Fehm
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - V Moebus
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - G von Minckwitz
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - N Burchardi
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| | - V Mueller
- University Medical Center Hamburg- Eppendorf, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Donauisar Clinic Deggendorf, Deggendorf, Germany; Clinic Memmingen, Memmingen, Germany; Clinic St. Elisabeth Straubing GmbH, Straubing, Germany; Rems-Murr-Clinic-Winnenden, Winnenden, Germany; Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany; Diakonieclinic Rotenburg (Wümme) gGmbH, Rotenburg, Germany; Clinic of The Otto-V.-Guericke-University, Magdeburg, Germany; Clinic Esslingen, Esslingen, Germany; Dr.-Horst-Schmidt-Clinic, Wiesbaden, Germany; Hannover Medical School, Hannover, Germany; University Clinic Mainz, Mainz, Germany; Johanniter-Clinic Genthin-Stendal, Stendal, Germany; Clinic for Hematological and Oncological Diseases, Koblenz, Germany; Radiology Alliance Hamburg, Hamburg, Germany; AGO Trafo (Translational Research Board), Germany; AGO-B (Breast Study Group), Germany
| |
Collapse
|
28
|
Schramm A, Mueller V, Huober J, Rack B, Fasching P, Taran F, Schneeweiss A, Aktas B, Janni W, Fehm T. P176 The DETECT-study concept – circulating tumor cells (CTCs) in metastatic breast cancer. Breast 2015. [DOI: 10.1016/s0960-9776(15)70217-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
29
|
Bednarz-Knoll N, Efstathiou A, Gotzhein F, Wilkman H, Mueller V, Kang Y, Pantel K. 328 Jagged1 expression and its relevance in metastatic progression of breast cancers. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70454-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
30
|
Abstract
Human migration attributable to climate events has recently received significant attention from the academic and policy communities (1-2). Quantitative evidence on the relationship between individual, permanent migration and natural disasters is limited (3-9). A 21-year longitudinal survey conducted in rural Pakistan (1991-2012) provides a unique opportunity to understand the relationship between weather and long-term migration. We link individual-level information from this survey to satellite-derived measures of climate variability and control for potential confounders using a multivariate approach. We find that flooding-a climate shock associated with large relief efforts-has modest to insignificant impacts on migration. Heat stress, however-which has attracted relatively little relief-consistently increases the long-term migration of men, driven by a negative effect on farm and non-farm income. Addressing weather-related displacement will require policies that both enhance resilience to climate shocks and lower barriers to welfare-enhancing population movements.
Collapse
Affiliation(s)
- V. Mueller
- International Food Policy Research Institute, Washington, DC 20006, USA
- Correspondence to:
| | - C. Gray
- Department of Geography, University of North Carolina, Chapel Hill, NC 27599
| | - K. Kosec
- International Food Policy Research Institute, Washington, DC 20006, USA
| |
Collapse
|
31
|
Melcher CA, Janni JW, Schneeweiss A, Fasching PA, Hagenbeck CD, Aktas B, Pantel K, Solomayer EF, Ortmann U, Jaeger BAS, Mueller V, Rack BK, Fehm TN. Abstract OT1-1-10: DETECT III - A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumorcells. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-ot1-1-10] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Despite a HER2-negative primary tumor approximately 20–30% of patients develop HER2-positive metastases (Zidan et al. 2005; Tewes et al. 2009). As previously described in the DETECT I trial (Fehm et al. 2010) determination of HER2 status on circulating tumor cells (CTCs) is one option for re-evaluating HER2-status in the metastatic setting. Currently it is unclear if HER2-targeted therapy based on the assessment of HER2-status of CTCs reveals a clinical benefit.
Trial design: DETECT III is a randomized, open-label, two arm phase III study comparing standard treatment alone vs. standard treatment plus HER2-targeted therapy with lapatinib in HER2-negative metastatic breast cancer patients with HER2-positive CTCs. Choices of chemotherapy and endocrine therapy include: docetaxel, paclitaxel, capecitabine, vinorelbine, non pegylated liposomal doxorubicin, letrozole, exemestane and anastrozole.
Main eligibility criteria: 1. metastatic breast cancer with HER2-negative primary tumor tissue and/or biopsies from metastatic sites or locoregional recurrences2. evidence of ≥ 1 HER2-positive CTC3. ≥ 1 evaluable metastatic lesion according to RECIST4. Tumor evaluation within 6 weeks before randomization
Specific aims: Objective: The objective of the trial is to prove the clinical efficacy of lapatinib in patients with metastasizing breast cancer who exhibit HER2-positive circulating tumor cells (CTC) although the primary tumor tissue and/or biopsies from metastatic sites were investigated for HER2 status and showed HER2-negativity.
Primary endpoint: Progression free survival
Secondary endpoints: Overall response rateClinical benefit rateOverall survivalDynamic of CTCQuality of lifeSafety and tolerability of lapatinib
Statistical methods: The primary endpoint will be analyzed by Kaplan-Meier method using the logrank test in order to compare the PFS distributions of the two arms. Efficacy, toxicity and other event rates are calculated, providing confidence intervals. In case of comparison between patient groups, these rates will be analyzed by Fisher's exact test or test. The Kaplan Meier analysis for all event related data will be carried out overall for the whole patient population. Furthermore a Cox regression analysis will be done using the following covariates Hormone receptor status (positive/negative)Number of prior chemotherapy lines for metastatic diseasePrior endocrine therapy for metastatic diseaseEndocrine treatment vs. cytotoxic treatmentOne metastatic site vs. multiple metastatic sitesBone metastases vs. no bone involvementPerformance status ECOG Score (0/> 0)
Present accrual and target accrual: As only half of the patients with HER2-negative metastatic breast cancer show CTC-positivity and of those approximately 32% will exhibit HER2-positive CTC (Fehm et al. 2010), screening of about 1420 patients is required to enroll 228 patients. First patient was screened in February 2012. As of July 27th 2012 117 patients were screened and 21 were found to have HER2-positive CTCs
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr OT1-1-10.
Collapse
Affiliation(s)
- CA Melcher
- University Hospital Duesseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; University Hospital Erlangen; University Hospital Essen, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Hospital Homburg, Germany; Ludwig-Maximilians-University Munich, Munich, Germany; University Hospital Hamburg-Eppendorf, Germany; University Hospital Tuebingen, Germany
| | - JW Janni
- University Hospital Duesseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; University Hospital Erlangen; University Hospital Essen, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Hospital Homburg, Germany; Ludwig-Maximilians-University Munich, Munich, Germany; University Hospital Hamburg-Eppendorf, Germany; University Hospital Tuebingen, Germany
| | - A Schneeweiss
- University Hospital Duesseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; University Hospital Erlangen; University Hospital Essen, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Hospital Homburg, Germany; Ludwig-Maximilians-University Munich, Munich, Germany; University Hospital Hamburg-Eppendorf, Germany; University Hospital Tuebingen, Germany
| | - PA Fasching
- University Hospital Duesseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; University Hospital Erlangen; University Hospital Essen, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Hospital Homburg, Germany; Ludwig-Maximilians-University Munich, Munich, Germany; University Hospital Hamburg-Eppendorf, Germany; University Hospital Tuebingen, Germany
| | - CD Hagenbeck
- University Hospital Duesseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; University Hospital Erlangen; University Hospital Essen, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Hospital Homburg, Germany; Ludwig-Maximilians-University Munich, Munich, Germany; University Hospital Hamburg-Eppendorf, Germany; University Hospital Tuebingen, Germany
| | - B Aktas
- University Hospital Duesseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; University Hospital Erlangen; University Hospital Essen, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Hospital Homburg, Germany; Ludwig-Maximilians-University Munich, Munich, Germany; University Hospital Hamburg-Eppendorf, Germany; University Hospital Tuebingen, Germany
| | - K Pantel
- University Hospital Duesseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; University Hospital Erlangen; University Hospital Essen, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Hospital Homburg, Germany; Ludwig-Maximilians-University Munich, Munich, Germany; University Hospital Hamburg-Eppendorf, Germany; University Hospital Tuebingen, Germany
| | - EF Solomayer
- University Hospital Duesseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; University Hospital Erlangen; University Hospital Essen, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Hospital Homburg, Germany; Ludwig-Maximilians-University Munich, Munich, Germany; University Hospital Hamburg-Eppendorf, Germany; University Hospital Tuebingen, Germany
| | - U Ortmann
- University Hospital Duesseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; University Hospital Erlangen; University Hospital Essen, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Hospital Homburg, Germany; Ludwig-Maximilians-University Munich, Munich, Germany; University Hospital Hamburg-Eppendorf, Germany; University Hospital Tuebingen, Germany
| | - BAS Jaeger
- University Hospital Duesseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; University Hospital Erlangen; University Hospital Essen, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Hospital Homburg, Germany; Ludwig-Maximilians-University Munich, Munich, Germany; University Hospital Hamburg-Eppendorf, Germany; University Hospital Tuebingen, Germany
| | - V Mueller
- University Hospital Duesseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; University Hospital Erlangen; University Hospital Essen, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Hospital Homburg, Germany; Ludwig-Maximilians-University Munich, Munich, Germany; University Hospital Hamburg-Eppendorf, Germany; University Hospital Tuebingen, Germany
| | - BK Rack
- University Hospital Duesseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; University Hospital Erlangen; University Hospital Essen, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Hospital Homburg, Germany; Ludwig-Maximilians-University Munich, Munich, Germany; University Hospital Hamburg-Eppendorf, Germany; University Hospital Tuebingen, Germany
| | - TN Fehm
- University Hospital Duesseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; University Hospital Erlangen; University Hospital Essen, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Hospital Homburg, Germany; Ludwig-Maximilians-University Munich, Munich, Germany; University Hospital Hamburg-Eppendorf, Germany; University Hospital Tuebingen, Germany
| |
Collapse
|
32
|
Ehlert K, Groll A, Mueller V, Rossig C, Juergens H. Safety Analysis of Upper Gastrointestinal Tract Endoscopy in Children and Adolescents After Allogeneic Hematopoietic Stem Cell Transplantation: A Five-Year, Single-Institution Survey. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
33
|
Mueller V, Ringemann C, Honigmann A, Schwarzmann G, Medda R, Leutenegger M, Polyakova S, Belov VN, Hell SW, Eggeling C. STED nanoscopy reveals molecular details of cholesterol- and cytoskeleton-modulated lipid interactions in living cells. Biophys J 2012; 101:1651-60. [PMID: 21961591 DOI: 10.1016/j.bpj.2011.09.006] [Citation(s) in RCA: 213] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2011] [Accepted: 08/25/2011] [Indexed: 01/10/2023] Open
Abstract
Details about molecular membrane dynamics in living cells, such as lipid-protein interactions, are often hidden from the observer because of the limited spatial resolution of conventional far-field optical microscopy. The superior spatial resolution of stimulated emission depletion (STED) nanoscopy can provide new insights into this process. The application of fluorescence correlation spectroscopy (FCS) in focal spots continuously tuned down to 30 nm in diameter distinguishes between free and anomalous molecular diffusion due to, for example, transient binding of lipids to other membrane constituents, such as lipids and proteins. We compared STED-FCS data recorded on various fluorescent lipid analogs in the plasma membrane of living mammalian cells. Our results demonstrate details about the observed transient formation of molecular complexes. The diffusion characteristics of phosphoglycerolipids without hydroxyl-containing headgroups revealed weak interactions. The strongest interactions were observed with sphingolipid analogs, which showed cholesterol-assisted and cytoskeleton-dependent binding. The hydroxyl-containing headgroup of gangliosides, galactosylceramide, and phosphoinositol assisted binding, but in a much less cholesterol- and cytoskeleton-dependent manner. The observed anomalous diffusion indicates lipid-specific transient hydrogen bonding to other membrane molecules, such as proteins, and points to a distinct connectivity of the various lipids to other membrane constituents. This strong interaction is different from that responsible for forming cholesterol-dependent, liquid-ordered domains in model membranes.
Collapse
Affiliation(s)
- V Mueller
- Department of Nanobiophotonics, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Mueller V, Riethdorf S, Rack B, Wolfgang J, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Mury D, Pantel K, Fehm T. P4-07-13: Prognostic Impact of Circulating Tumor Cells Assessed with the Cell Search Assay and Adna Test Breast in Metastatic Breast Cancer Patients – The DETECT Study. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-07-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Over the last decade circulating tumor cells (CTC) were established as a prognostic factor in breast cancer patients. However, there are very limited studies comparing different test methods, although several are available.The DETECT trial for metastatic breast cancer patients was designed to investiate the prognostic impact of CTC. Here, we report on the prognostic relevance of CTC testing with different detection methods.
Material and Methods: Patients with primary metastatic breast cancer or metastatic recurrence were prospectively enrolled in this multicenter trial. CTC were detected using the FDA-approved Cell Search® assay applying immunocytochemistry and the RNA-based Adna Test Breast Cancer™. After a median follow-up of 11 months the first survival data are now presented.
Results: Both methods could be performed in 221 patients. Using the CellSearch™ assay 116 of 221 patients were CTC-positive based on the cut-off level of 5 cells. Presence of CTC was associated with the site of metastatic disease. The OS was 15.4 months in CTC positive pts. (95%-CI: 13.5−17.1 mths) compared to 20.4 mths. in CTC negative pts. (19.1−21.9 mths.; p<0.001). In the multivariate analysis presence of CTC was the only independent predictor for overall survival (HR: 3.4, 95%-CI: 1.7−6.3) including tumorbiological factors, menopausal status, number and sites of metastatic disease. The progression-free survival was not correlated with CTC status in our cohort receiving different types of systemic treatment (p=0.197). When the AdnaTest Breast was performed, 88 of 221 (40%) patients were CTC positive. Except for HER2 status, no correlation could be observed between CTC positivity and any of the clinicopathological factors. CTC positivity assessed by the AdnaTest Breast has no impact on PFS and OS. A multivariate analysis was therefore not performed.
Conclusions: Currently, several different tests are available for CTC detection. Only a few tests have been approved by the FDA and been validated in large clinical trials. Therfore, it will be important to compare new techniques with the Cell Search assay.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-07-13.
Collapse
Affiliation(s)
- V Mueller
- 1University Medical Center Hamburg-Eppendorf; LMU Munich; University Medical Center Düsseldorf; Hospital Erlangen, Friedrich-Alexander University Erlangen Nuremberg, Erlangen; University Medical Center Homburg/Saar; University Medical Center Essen; University Medical Center Tübingen, All Authors on Behalf of the DETECT Study Group
| | - S Riethdorf
- 1University Medical Center Hamburg-Eppendorf; LMU Munich; University Medical Center Düsseldorf; Hospital Erlangen, Friedrich-Alexander University Erlangen Nuremberg, Erlangen; University Medical Center Homburg/Saar; University Medical Center Essen; University Medical Center Tübingen, All Authors on Behalf of the DETECT Study Group
| | - B Rack
- 1University Medical Center Hamburg-Eppendorf; LMU Munich; University Medical Center Düsseldorf; Hospital Erlangen, Friedrich-Alexander University Erlangen Nuremberg, Erlangen; University Medical Center Homburg/Saar; University Medical Center Essen; University Medical Center Tübingen, All Authors on Behalf of the DETECT Study Group
| | - J Wolfgang
- 1University Medical Center Hamburg-Eppendorf; LMU Munich; University Medical Center Düsseldorf; Hospital Erlangen, Friedrich-Alexander University Erlangen Nuremberg, Erlangen; University Medical Center Homburg/Saar; University Medical Center Essen; University Medical Center Tübingen, All Authors on Behalf of the DETECT Study Group
| | - PA Fasching
- 1University Medical Center Hamburg-Eppendorf; LMU Munich; University Medical Center Düsseldorf; Hospital Erlangen, Friedrich-Alexander University Erlangen Nuremberg, Erlangen; University Medical Center Homburg/Saar; University Medical Center Essen; University Medical Center Tübingen, All Authors on Behalf of the DETECT Study Group
| | - E Solomayer
- 1University Medical Center Hamburg-Eppendorf; LMU Munich; University Medical Center Düsseldorf; Hospital Erlangen, Friedrich-Alexander University Erlangen Nuremberg, Erlangen; University Medical Center Homburg/Saar; University Medical Center Essen; University Medical Center Tübingen, All Authors on Behalf of the DETECT Study Group
| | - B Aktas
- 1University Medical Center Hamburg-Eppendorf; LMU Munich; University Medical Center Düsseldorf; Hospital Erlangen, Friedrich-Alexander University Erlangen Nuremberg, Erlangen; University Medical Center Homburg/Saar; University Medical Center Essen; University Medical Center Tübingen, All Authors on Behalf of the DETECT Study Group
| | - S Kasimir-Bauer
- 1University Medical Center Hamburg-Eppendorf; LMU Munich; University Medical Center Düsseldorf; Hospital Erlangen, Friedrich-Alexander University Erlangen Nuremberg, Erlangen; University Medical Center Homburg/Saar; University Medical Center Essen; University Medical Center Tübingen, All Authors on Behalf of the DETECT Study Group
| | - D Mury
- 1University Medical Center Hamburg-Eppendorf; LMU Munich; University Medical Center Düsseldorf; Hospital Erlangen, Friedrich-Alexander University Erlangen Nuremberg, Erlangen; University Medical Center Homburg/Saar; University Medical Center Essen; University Medical Center Tübingen, All Authors on Behalf of the DETECT Study Group
| | - K Pantel
- 1University Medical Center Hamburg-Eppendorf; LMU Munich; University Medical Center Düsseldorf; Hospital Erlangen, Friedrich-Alexander University Erlangen Nuremberg, Erlangen; University Medical Center Homburg/Saar; University Medical Center Essen; University Medical Center Tübingen, All Authors on Behalf of the DETECT Study Group
| | - T Fehm
- 1University Medical Center Hamburg-Eppendorf; LMU Munich; University Medical Center Düsseldorf; Hospital Erlangen, Friedrich-Alexander University Erlangen Nuremberg, Erlangen; University Medical Center Homburg/Saar; University Medical Center Essen; University Medical Center Tübingen, All Authors on Behalf of the DETECT Study Group
| |
Collapse
|
35
|
Ruckhaeberle E, Mueller V, Schmidt M, Saenger N, Hanker L, Gaetje R, Ahr A, Holtrich U, Karn T, Rody A, Kaufmann M. P3-01-12: Prognostic Impact of RANK, RANKL and OPG Gene Expression in ER Positive Primary Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-01-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The cell surface receptor RANK (receptor activator of NFκB), its ligand (RANKL) and the decoy receptor of RANKL osteoprotegerin (OPG) play an important functional role in bone physiology and in bone metastasis by regulating osteoclasts. Just recently it was shown that tumor-infiltrating lymphocytes can stimulate breast cancer metastases through RANK-RANKL signalling.
Material and methods: We analyzed gene expression of RANK, RANKL and OPG in a combined Affymetrix dataset of 307 ER positive breast cancers from our institutions which were either untreated of treated with chemotherapy. Kaplan Meier analysis of disease free survival and Cox regression analysis was applied to examine the prognostic value of the different markers.
Results: We observed no significant difference in survival when samples were analyzed according to either RANK or RANKL mRNA expression. In contrast when samples were stratified in quartiles of OPG expression a positive linear relationship of survival with the expression of OPG was observed. Moreover since OPG demonstrated a bimodal type of expression a cutoff value can be derived from the expression data. Using this cutoff value a hazard ration of 2.14 (95% CI 1.27−3.61; P=0.004 for low OPG expression was detected. OPG expression correlated with lower proportion of grade 3 tumors (15.7% vs 27%; P=0.022) and a higher proportion of PgR positive samples (86.2% vs 71.4%; P=0.002). No significant differences were observed for lymph node status, age, tumor size and HER2 status. In multivariate analysis only lymph node status remained significant while OPG, Ki67, age, grade, and PgR only displayed a trend towards significance.
Conclusion: Expression of osteoprotegerin seems to correlate with good prognosis in ER postive breast cancer. These data are in line with in vitro studies demonstration that OPG inhibits RANKL induced migration of tumor cells.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-01-12.
Collapse
Affiliation(s)
- E Ruckhaeberle
- 1Department of Gynecological Oncology, Frankfurt, Germany; Department of Obstetrics and Gynecology, Hamburg, Germany; Department of Obstetrics and Gynecology, Mainz, Germany; Department of Obstetrics and Gynecology, Homburg/Saar, Germany
| | - V Mueller
- 1Department of Gynecological Oncology, Frankfurt, Germany; Department of Obstetrics and Gynecology, Hamburg, Germany; Department of Obstetrics and Gynecology, Mainz, Germany; Department of Obstetrics and Gynecology, Homburg/Saar, Germany
| | - M Schmidt
- 1Department of Gynecological Oncology, Frankfurt, Germany; Department of Obstetrics and Gynecology, Hamburg, Germany; Department of Obstetrics and Gynecology, Mainz, Germany; Department of Obstetrics and Gynecology, Homburg/Saar, Germany
| | - N Saenger
- 1Department of Gynecological Oncology, Frankfurt, Germany; Department of Obstetrics and Gynecology, Hamburg, Germany; Department of Obstetrics and Gynecology, Mainz, Germany; Department of Obstetrics and Gynecology, Homburg/Saar, Germany
| | - L Hanker
- 1Department of Gynecological Oncology, Frankfurt, Germany; Department of Obstetrics and Gynecology, Hamburg, Germany; Department of Obstetrics and Gynecology, Mainz, Germany; Department of Obstetrics and Gynecology, Homburg/Saar, Germany
| | - R Gaetje
- 1Department of Gynecological Oncology, Frankfurt, Germany; Department of Obstetrics and Gynecology, Hamburg, Germany; Department of Obstetrics and Gynecology, Mainz, Germany; Department of Obstetrics and Gynecology, Homburg/Saar, Germany
| | - A Ahr
- 1Department of Gynecological Oncology, Frankfurt, Germany; Department of Obstetrics and Gynecology, Hamburg, Germany; Department of Obstetrics and Gynecology, Mainz, Germany; Department of Obstetrics and Gynecology, Homburg/Saar, Germany
| | - U Holtrich
- 1Department of Gynecological Oncology, Frankfurt, Germany; Department of Obstetrics and Gynecology, Hamburg, Germany; Department of Obstetrics and Gynecology, Mainz, Germany; Department of Obstetrics and Gynecology, Homburg/Saar, Germany
| | - T Karn
- 1Department of Gynecological Oncology, Frankfurt, Germany; Department of Obstetrics and Gynecology, Hamburg, Germany; Department of Obstetrics and Gynecology, Mainz, Germany; Department of Obstetrics and Gynecology, Homburg/Saar, Germany
| | - A Rody
- 1Department of Gynecological Oncology, Frankfurt, Germany; Department of Obstetrics and Gynecology, Hamburg, Germany; Department of Obstetrics and Gynecology, Mainz, Germany; Department of Obstetrics and Gynecology, Homburg/Saar, Germany
| | - M Kaufmann
- 1Department of Gynecological Oncology, Frankfurt, Germany; Department of Obstetrics and Gynecology, Hamburg, Germany; Department of Obstetrics and Gynecology, Mainz, Germany; Department of Obstetrics and Gynecology, Homburg/Saar, Germany
| |
Collapse
|
36
|
Hoffmann B, Domanska OM, Albay Z, Mueller V, Guethlin C, Thomas EJ, Gerlach FM. The Frankfurt Patient Safety Climate Questionnaire for General Practices (FraSiK): analysis of psychometric properties. BMJ Qual Saf 2011; 20:797-805. [DOI: 10.1136/bmjqs.2010.049411] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
37
|
Jaenicke F, Mueller V, Abenhardt W, Kaufmann M, Schoenegg W, Schneeweiss A. Abstract P3-14-19: Long-Time Tumor Remissions under Trastuzumab Therapy in HER2- Positive Locally Recurrent or Metastatic Breast Cancer: First Interim Analysis of the HER-OS Database. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p3-14-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Currently, locally recurrent or metastatic breast cancer is incurable and considered a chronic disease. Although pallitative endocrine therapies and chemotherapies cause tumor remissions, they fail to considerably prolong survival. However, when patients, suffering from HER2-positive locally recurrent or metastatic breast cancer, were treated with trastuzumab, impressive improvements of overall survival were reported. Of special interest are long-term tumor remissions under trastuzumab therapy, which have not frequently been reported for other regimens. The HER-OS database for long-term survivors was set up to collect data from patients with long-time tumor remission under trastuzumab therapy and to analyze factors, which are correlated with these long-term remissions.
Methods
This is the first interim analysis of datasets from 220 patients in 71 german centers, registered in HER-OS. Eligible were patients with HER2- positive locally recurrent or metastatic breast cancer, who had remissions (complete or partial response) for at least 2 years under trastuzumab therapy. Retrospective as well as partial retro-/prospective documentation was allowed. From December 2006 until April 2010 220 patients were sufficiently documented to be analyzed for demographic data, tumor biology, adjuvant and palliative treatments (surgery, radiation therapy, endocrine therapy, chemotherapy) as well as time to progression under trastuzumab therapy and overall survival.
Results
Patients had a median age of 53.2 years and 72.3% were younger than 60 years at time of first diagnosis. 10.0% of patients had primary distant metastasis at time of first diagnosis and in general patients were in good physical condition (51.8 % with ECOG performance status 0). During breast cancer pretreatment in the adjuvant setting, 86.4% of the patients had primary surgery, 63.2% received adjuvant chemotherapy and 40.9% received adjuvant endocrine therapy. In the metastatic situation 5.5% of patients had surgery, 51.8% received chemotherapy and 32.7% endocrine therapy.
The patients had a median age of 58.5 years at start of trastuzumab application and the median duration of trastuzumab treatment was 47.1 months. Secondary CNS metastases were reported for 13.2% of patients and occurred after a median trastuzumab treatment duration of 26.9 months.
As only 86 of 220 patients in the population had progressive disease at time of analysis, the median time to progression was not reached yet. Still, quartile estimates indicate a median time to progression of 58.5 months [95%-CI (47.8-114.5)]. Conclusion
220 patients with tumor remissions for at least 24 months under trastuzumab therapy were evaluated in the first interim analysis of the HER-OS database. The population was in general of young age and in a good physical condition. At the time of analysis secondary CNS metastases were reported only in 13.2% of the patients. The estimated median time to progression is 58.5 months and will be confirmed in the future. In conclusion, these data indicate that treatment with trastuzumab contributes to manage HER2-positive locally recurrent or metastatic breast cancer as chronic disease.
Updated results will be presented at the meeting.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P3-14-19.
Collapse
Affiliation(s)
- F Jaenicke
- University Medical Center Hamburg-Eppendorf, Hamburg; MVZ MOP Elisenhof, Munich; University of Frankfurt, Frankfurt a.M.; DRK Clinics Berlin Westend - Breast Center, Berlin; University of Heidelberg
| | - V Mueller
- University Medical Center Hamburg-Eppendorf, Hamburg; MVZ MOP Elisenhof, Munich; University of Frankfurt, Frankfurt a.M.; DRK Clinics Berlin Westend - Breast Center, Berlin; University of Heidelberg
| | - W Abenhardt
- University Medical Center Hamburg-Eppendorf, Hamburg; MVZ MOP Elisenhof, Munich; University of Frankfurt, Frankfurt a.M.; DRK Clinics Berlin Westend - Breast Center, Berlin; University of Heidelberg
| | - M Kaufmann
- University Medical Center Hamburg-Eppendorf, Hamburg; MVZ MOP Elisenhof, Munich; University of Frankfurt, Frankfurt a.M.; DRK Clinics Berlin Westend - Breast Center, Berlin; University of Heidelberg
| | - W Schoenegg
- University Medical Center Hamburg-Eppendorf, Hamburg; MVZ MOP Elisenhof, Munich; University of Frankfurt, Frankfurt a.M.; DRK Clinics Berlin Westend - Breast Center, Berlin; University of Heidelberg
| | - A. Schneeweiss
- University Medical Center Hamburg-Eppendorf, Hamburg; MVZ MOP Elisenhof, Munich; University of Frankfurt, Frankfurt a.M.; DRK Clinics Berlin Westend - Breast Center, Berlin; University of Heidelberg
| |
Collapse
|
38
|
Woelber L, Jung S, Eulenburg C, Mueller V, Schwarz J, Jaenicke F, Mahner S. Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer. Eur J Surg Oncol 2010; 36:583-8. [PMID: 20488646 DOI: 10.1016/j.ejso.2010.04.012] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2009] [Accepted: 04/22/2010] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND Despite radical surgical and chemotherapeutic treatment of ovarian cancer, the majority of patients develop recurrent disease. Secondary cytoreductive surgery can result in favourable outcome in selected patients, but information regarding feasibility, safety and perioperative outcome of these often complex procedures is limited. METHODS Surgical parameters in patients with recurrent epithelial ovarian cancer selected for secondary cytoreduction were analysed and compared to patients undergoing primary cytoreduction. RESULTS In total, 222 patients undergoing radical cytoreduction were analysed (48 patients for relapsed disease and 174 patients at primary diagnosis of advanced ovarian cancer). The range of surgical procedures was similar in both groups. In 48% of secondary cytoreductions 'optimal surgical results' (residual tumour <1 cm) were obtained and 33% of the patients had no residual disease compared to 82% and 58% at primary cytoreduction. There was no significant difference in perioperative complication rates. The duration of surgery was shorter and the number of transfused blood products was smaller at secondary cytoreduction (p < 0.001 and p = 0.001). CONCLUSION Secondary cytoreduction in relapsed ovarian cancer is safe and feasible and perioperative outcome is not inferior compared to primary cytoreduction. Surgery-associated morbidity should represent a minor aspect in the selection and counselling of patients regarding treatment options for recurrent ovarian cancer.
Collapse
Affiliation(s)
- L Woelber
- Department of Gynaecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | | | | | | | | | | | | |
Collapse
|
39
|
Fehm TN, Rack BK, Janni W, Fasching PA, Zeitz J, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Mueller V. Prospective evaluation of serum tissue inhibitor of metalloproteinase-1 (TIMP-1) and carbonic anhydrase IX (CAIX) in correlation to circulating tumor cells in patients with metastatic breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
40
|
Mavrova L, Karn T, Hanker L, Ruckhäberle E, Mueller V, Holtrich U, Kaufmann M, Rody A. Prognostic relationship of SATB1 gene expression and estrogen receptor status in breast cancer cells. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Rody A, Karn T, Liedtke C, Ruckhäberle E, Hanker L, Pusztai L, Mueller V, Schmidt M, Holtrich U, Kaufmann M. Clinically relevant gene signatures in triple-negative and basal-like breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Aktas B, Mueller V, Schumacher K, Tewes M, Zeitz J, Kasimir-Bauer S, Rack B, Janni W, Solomayer E, Fehm T. ER and PR Expression Profile of Circulating Tumor Cells in Metastatic Breast Cancer Patients in Comparison to the Primary Tumor. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-3009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Introduktion: Several studies have indicated that the expression of predictive markers including ER and PR can change during course of disease. Therefoore, reassesment of of the prediktive markers at the time of disease progression might help to optimize treatment decisions. Metastatic tissue may be difficult to obtain for repeated analysis. In this context, characterization of circulating tumor cells (CTCs) could be of relevance. Therefore, the purpose of the present study was: (1) to reevaluate the ER/PR expression by circulating tumor cells and (2) to compare the hormone receptor status expression profile of CTC with the primary tumor. Materials and Methods: We ecaluated, 166 blood samples from metastatic breast cancer patients at the time of first diagnosis of first metastatic disease or disease progression. All samples underwent immunomagnetic enrichment using the AdnaTest BreastCancerSelect (AdnaGen AG, Germany) within 4 hours after blood withdrawal followed by RNA isolation and subsequent gene expression analysis by reverse transcription and Multiplex-PCR in separated tumor cells using the AdnaTest BreastCancerDetect. CTC were analyzed for the three breast cancer associated markers: GA733-2, Muc-1, Her-2 and β-actin as an internal PCR control. Expression of the estrogen (ER) and progesterone (PR) receptor was assessed in an additional RT-PCR. The analysis of PCR products was performed by capillary electrophoresis on the Agilent Bioanalyzer 2100. Results: The overall detection rate for CTC was 38% (63/166 patients) with the expression rates of 79% for EpCAM (50/63 patients), 77% for MUC1 (49/63 patients), 49% for HER2 (31/63 patients), 23% for ER (15/65 patients) and 11% for PR (7/65 patients), respectively. Comparisons with the primary tumor were only performed in CTC+ patients (n=65). In 41 of 65 (63%) patients with ER+ tumors, CTC were ER- and 38/65 (58%) patients with PR+ tumors did not express PR on CTC. Primary tumors and CTC displayed a concordant ER and PR status in only 34% and 61% of cases, respectively. Conclusion: Most of the CTC were ER/PR-negative despite the presence of an ER/PR-positive primary tumor. The predictive value of hormone receptor status expression profile of CTC for palliative endocrine therapy has to be prospectively evaluated.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3009.
Collapse
Affiliation(s)
- B. Aktas
- 1University Hospital Essen, University of Duisburg-Essen, Germany
| | | | | | - M. Tewes
- 4University Hospital Essen, University of Duisburg-Essen, Germany
| | - J. Zeitz
- 2University Hospital Hamburg, Germany
| | - S. Kasimir-Bauer
- 1University Hospital Essen, University of Duisburg-Essen, Germany
| | - B. Rack
- 6University Hospital Munich, Germany
| | - W. Janni
- 5University Hospital Duesseldorf, Germany
| | | | - T. Fehm
- 3University Hospital Tuebingen, Germany
| |
Collapse
|
43
|
Rody A, Karn T, Solbach C, Ruckhaeberle E, Hanker L, Mueller V, Schmidt M, Gaetje R, Holtrich U, Kaufmann M. The Luminal B Marker NHERF1 Predicts Endocrine Resistance. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-3164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Tumors of the luminal B subtype of ER postive breast cancer are characterized by high proliferation as compared to the luminal A subtype. The luminal B have a worse prognosis. We aimed to identify genes specifically expressed in the luminal B subtype of breast cancers and analyze the prognostic impact of these genes and their relationship to endocrine therapy.Methods:121 genes overexpressed in LumB tumors were identified in a test set of 171 Breast cancer samples and reproducibly obtained in four independent validation datasets. The scaffold protein NHERF1 was analyzed in a large scale meta-analysis of microarray datasets encompassing n=3030 breast cancer samples.Results:NHERF1 is an ER regulated gene located on chromosome 17 coding for a scaffold protein involved in growth factor signal transduction. NHERF1 expression among ER positive tumors is associated with larger tumor size, higher histolocigal grading, and HER2 expression. A prognostic value of NHERF1 was observed among ER positive tumors (univariate HR 1.49, 95% CI 1.23-1.80, P<0.001) but not among ER negative samples. NHERF1 remained significant in multivariate analysis (HR 1.37, 95% CI 1.05-1.79, P=0.020) and is not a surrogate marker for high proliferation. A benefit of endocrine treatment seems to be restricted to NHERF1 negative tumors.Conclusions:Markers like NHERF1 specific for the luminal B subtype of breast cancer correlate with poor prognosis and seem to be predictive for endocrine treatment response.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3164.
Collapse
Affiliation(s)
- A. Rody
- 1J.W. Goethe-University, Germany
| | - T. Karn
- 1J.W. Goethe-University, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Fehm T, Mueller V, Kasimir-Bauer S, Janni W, Löhberg C, Gebauer G, Rack B, Stickeler E, Ortmann O, Riethdorf S, Solomayer E, Klein C, Schindlbeck C, Kreipe H, Wallwiener D, Pantel K. Detect-Study: Comparison of Two Techniques for the Evaluation of the HER2 Expression on Circulating Tumor Cells in Metastatic Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-3004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction:There is a growing body of evidence that the HER2 status can change during disease progression (Gancberg et al. 2003). However, the re-assessment of the HER2 status to evaluate the eligibility for HER2 targeted therapy by a tissue biopsy of the metastatic lesion may not always be feasible. In this context, determination of the HER2 status using CTCs might be a strategy with potential clinical application. So far, no large prospective studies were performed comparing different methods for CTCs detection and characterization. The aim of this trial was to determine the HER2 status of CTCs in metastatic breast cancer patients using the antibody based CellSearch©assay and the RT-PCR approach AdnaTest Breast Cancer and to assess the concordance rate between these two techniques. Both techniques are frequently used in clinical trials.Method:A total of 252 metastatic breast cancer patients from 9 different certified breast cancer centers (Düsseldorf, Erlangen, Essen, Freiburg, Hamburg, Heidelberg, Muenchen, Regensburg, Tuebingen) were enrolled in this prospective open trial from 01/2008 until 04/2009. HER2 status of CTCs was assessed using both the FDA approved CellSearch©Assay (Veridex, Warren, NJ, USA) and the AdnaTest Breast Cancer (Adnagen, Langenhagen, Germany) according to the manufacturers' instructions. A web based databank was designed for data management and online-documentation (www. detect-study.de). The study design was approved by the ethics' comittee (2007/B01).Results:Using the CellSearch©Assay, 133 of 252 (55%) metastatic patients had CTCs at the time of first diagnosis or disease progression. HER2 positivity was observed in 39% of CTC positive patients (52 of 133) but only 22 of these had initially a HER2 positive primary tumor. Eighty-eight of 225 (39%) patients were CTC positive using the AdnaTest Breast Cancer. The HER2 positivity rate was 47% (41 of 88). Eight of these patients had a HER2 positive primary tumor whereas 33 patients were initially HER2 negative or unknown. Summarizing the data, the rate of breast cancer patients with HER2 negative primary tumors but HER2 positive circulating tumor cells was 38% (32 of 61) and 48% (28 of 41) using the CellSearch Assay and the AdnaTest Breast Cancer, respectively. Considering only those patients who had CTCs on both tests (n=61), the concordance rate regarding HER2 expression was 51% (32 of 61).Conclusion:Based on CTCs the HER2 status can change during disease progression. However, using different techniques, disconcordant results were obtained. To prove the clinical value of these CTC assays and to implement the HER2 status of CTCs as a stratification parameter in future clinical trials, it will be mandatory to correlate clinical response to HER2 targetd therapy on each method in patients with HER2 positive CTCs.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3004.
Collapse
|
45
|
Mueller V, Riethdorf S, Rack B, Janni W, Fasching P, Pantel K, Gebauser G, Solomayer E, Aktas B, Kasemier-Bauer S, Fehm T. Prospective Evaluation of Serum HER2 and HER2 Expression on Circulating Tumor Cells in Patients with Metastatic Breast Cancer within the DETECT Study. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-3050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Assessment of HER2 status at the time of metastatic disease might help to optimize treatment decisions in patients with no HER2 status determined at first diagnosis and could also be helpful since HER2 status may change during disease progression. In this context, determination of serum HER2 or the evaluation of HER2 status on circulating tumor cells (CTC) is of potential relevance especially for optimizing HER2-directed therapy. The aim of this study was therefore to determine the serum HER2 status and the HER2 status of CTC from corresponding patients.Methods: Blood samples were obtained in a prospective multicenter setting from 251 patients with metastatic breast cancer at the time of disease progression. Serum HER2 was determined using the commercial HER2 ELISA-kit (Oncogene Science). CTC were detected and HER2 expression was assessed with the CellSearch™ system (Veridex).Results: 119 of 251 (47%) metastatic patients had elevated serum HER2 levels above 15 ng/mL. Serum HER2 was elevated in 49 (66%) of 74 patients with HER2 positive primary tumors, in 57 of 148 (39%) with HER2 negative primary tumors and in 13 of 29 (45%) patients with unknown HER2 primary tumor status. CTC were detected in 133 of 243 evaluable patients (5 or more cells), in these HER2 overexpression on CTC (strong overexpression in at least one cell) was detected in 52 cases (39%). Only 20 of these patients had a HER2 positive primary tumor. In patients with HER2 positive CTC, serum levels were above the cut off in 34 of 52 (65%), while in those with HER2 negative CTC 44 of 81 (54%) showed elevated HER2 serum levels. Concordance between HER2 status of circulating tumor cells and elevated serum HER2 was seen in 71 of 133 patients (53%).Conclusions: Our study demonstrates with a prospective design that also in patients with initially negative HER2 tumor status elevated serum HER2 levels and/or HER2 positive CTC can be detected at the time of metastatic disease. This is of clinical relevance since these patients in current practice do not have access to HER2 targeted therapy.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3050.
Collapse
Affiliation(s)
- V. Mueller
- 1University Medical Center Hamburg, Germany
| | | | | | - W. Janni
- 4Heinrich Heine University, Germany
| | | | | | | | | | - B. Aktas
- 8University Medical Center, Germany
| | | | - T. Fehm
- 7University Medical Center, Germany
| |
Collapse
|
46
|
Fehm T, Mueller V, Marches R, Klein G, Gueckel B, Neubauer H, Solomayer E, Becker S. Tumor cell dormancy: implications for the biology and treatment of breast cancer. APMIS 2008; 116:742-53. [PMID: 18834416 DOI: 10.1111/j.1600-0463.2008.01047.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Despite progress made in the therapy of solid tumors such as breast cancer, the prognosis of patients even with small primary tumors is still limited by metastatic relapse often long after removal of the primary tumor. Therefore, it has been hypothesized that primary tumors shed tumor cells already at an early stage into the blood circulation. A subset of these disseminated tumor cells may persist in a state of so-called "dormancy". Based on cell culture and animal models, dormancy can occur at two different stages. Single dormant cells are defined as cells with a lack of proliferation and apoptosis with the cells undergoing cell cycle arrest. The micrometastasis model defines tumor cell dormancy as a state of balanced apoptosis and proliferation of micrometastasis resulting in no net increase of tumor mass. Mechanisms leading to a growth activation of dormant tumor cells and the outgrowth of manifest metastases are not completely understood. Genetic predisposition of the dormant cells as well as immunological and angiogenetic influences of the surrounding environment may contribute to this phenomenon. In this review, we summarize findings on different factors for tumor cell dormancy and potential therapeutic implications that should help to reduce metastatic relapse in cancer patients.
Collapse
Affiliation(s)
- T Fehm
- Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Rody A, Karn T, Ruckhaeberle E, Mueller V, Gaetje R, Holtrich U, Kaufmann M. Gene expression of topoisomerase II alpha by microarray analysis is highly prognostic in estrogen receptor (ER)+ breast cancer – prognostic value of Topoisomerase II alpha. Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-0028-1088698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
48
|
Mueller V, Riethdorf S, Loibl S, Komor M, Houber J, Schrader I, Conrad U, Untch M, vMinckwitz G, Pantel K. Prospective monitoring of circulating tumor cells in breast cancer patients treated with primary systemic therapy—A translational project of the German Breast Group study GeparQuattro. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.21085] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
21085 Background: The impact of circulating tumor cells (CTC) in patients with primary breast cancer is still unclear. Primary systemic treatment (PST) allows the assessment of therapeutic efficacy in breast cancer patients without long follow-up periods. Here we present first results on the presence of CTC in peripheral blood of patients enrolled in the “GeparQuattro” study. Methods: This study incorporates three different chemotherapy approaches and additional Trastuzumab (Herceptin®) treatment for patients with HER-2/neu-positive tumors. Recruitment finished in November 2006 and not all patients have completed therapy yet. We used the CellSearch™ system to evaluate CTC before PST from 245 patients and after PST from 67 patients. CTC from 45 samples were also examined for HER-2/neu expression by immunocytochemistry in the CellSearch™ system. Results: Before PST we detected CTC in 54/245 patients (22%). CTC numbers in 7.5 mL blood ranged between 1 and 200 (mean 6.5). In 8 CTC-positive samples (3.3%) = 5 CTC were found. Her-2/neu-positive CTC were observed in 25/45 cases (55.6%). CTC could be detected in 7/67 patients (10.4%) after PST (1 or 2 CTC). Before and after PST blood was analyzed from 43 patients, 27 of them were CTC-negative at both time points. Ten initially CTC-positive cases were CTC-negative after PST whereas 6 cases were detected CTC-positive after PST although no CTC could be found before PST. Conclusions: With the CellSearch™ system CTC can be detected in non-metastatic breast cancer patients at primary diagnosis and also after PST. To our knowledge, this is the largest study evaluating the presence of CTC in this context. With the availability of response information from more patients, it will be possible to examine the correlation between the incidence of CTC and response as well as kinetics of HER-2/neu expression during Trastuzumab treatment. [Table: see text]
Collapse
Affiliation(s)
- V. Mueller
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany; J. W. Goethe University, Frankfurt, Germany; German Breast Group, Neu Isenburg, Germany; University Medical Center, Tübingen, Germany; Henriettenstiftung, Hannover, Germany; St. Barbara-Klinik, Heessen, Germany; Heliosklinik Buch, Berlin, Germany
| | - S. Riethdorf
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany; J. W. Goethe University, Frankfurt, Germany; German Breast Group, Neu Isenburg, Germany; University Medical Center, Tübingen, Germany; Henriettenstiftung, Hannover, Germany; St. Barbara-Klinik, Heessen, Germany; Heliosklinik Buch, Berlin, Germany
| | - S. Loibl
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany; J. W. Goethe University, Frankfurt, Germany; German Breast Group, Neu Isenburg, Germany; University Medical Center, Tübingen, Germany; Henriettenstiftung, Hannover, Germany; St. Barbara-Klinik, Heessen, Germany; Heliosklinik Buch, Berlin, Germany
| | - M. Komor
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany; J. W. Goethe University, Frankfurt, Germany; German Breast Group, Neu Isenburg, Germany; University Medical Center, Tübingen, Germany; Henriettenstiftung, Hannover, Germany; St. Barbara-Klinik, Heessen, Germany; Heliosklinik Buch, Berlin, Germany
| | - J. Houber
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany; J. W. Goethe University, Frankfurt, Germany; German Breast Group, Neu Isenburg, Germany; University Medical Center, Tübingen, Germany; Henriettenstiftung, Hannover, Germany; St. Barbara-Klinik, Heessen, Germany; Heliosklinik Buch, Berlin, Germany
| | - I. Schrader
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany; J. W. Goethe University, Frankfurt, Germany; German Breast Group, Neu Isenburg, Germany; University Medical Center, Tübingen, Germany; Henriettenstiftung, Hannover, Germany; St. Barbara-Klinik, Heessen, Germany; Heliosklinik Buch, Berlin, Germany
| | - U. Conrad
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany; J. W. Goethe University, Frankfurt, Germany; German Breast Group, Neu Isenburg, Germany; University Medical Center, Tübingen, Germany; Henriettenstiftung, Hannover, Germany; St. Barbara-Klinik, Heessen, Germany; Heliosklinik Buch, Berlin, Germany
| | - M. Untch
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany; J. W. Goethe University, Frankfurt, Germany; German Breast Group, Neu Isenburg, Germany; University Medical Center, Tübingen, Germany; Henriettenstiftung, Hannover, Germany; St. Barbara-Klinik, Heessen, Germany; Heliosklinik Buch, Berlin, Germany
| | - G. vMinckwitz
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany; J. W. Goethe University, Frankfurt, Germany; German Breast Group, Neu Isenburg, Germany; University Medical Center, Tübingen, Germany; Henriettenstiftung, Hannover, Germany; St. Barbara-Klinik, Heessen, Germany; Heliosklinik Buch, Berlin, Germany
| | - K. Pantel
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany; J. W. Goethe University, Frankfurt, Germany; German Breast Group, Neu Isenburg, Germany; University Medical Center, Tübingen, Germany; Henriettenstiftung, Hannover, Germany; St. Barbara-Klinik, Heessen, Germany; Heliosklinik Buch, Berlin, Germany
| |
Collapse
|
49
|
Abraha RS, Thomssen C, Harbeck N, Mueller V, Baack K, Schmitt M, Jänicke F. Mikromethode zur Bestimmung von uPA und PAI-1 aus präoperativen Stanzbiopsien bei Mammakarzinomen. Geburtshilfe Frauenheilkd 2003. [DOI: 10.1055/s-2003-815236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
50
|
Mueller V, Hoepffner W, Kiess W, Keller E. Prediction of height velocity of prepubertal children with growth hormone deficiency in the first year of treatment with recombinant human growth hormone. J Pediatr Endocrinol Metab 2000; 13:893-7. [PMID: 10968477 DOI: 10.1515/jpem.2000.13.7.893] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
AIM Several methods have been developed to predict the outcome of growth hormone (GH) therapy in children with growth hormone deficiency (GHD). METHODS Over 50 factors for each of 92 prepubertal patients with GHD (26 patients with total and 45 patients with partial GHD, 21 patients with neurosecretory dysfunction) were collected and included in multiple regression analyses and other nonlinear models to predict height velocity (HV) (cm/yr) in the first year of treatment. Afterwards the model was validated by two other cohorts of patients from other universities, which followed the same treatment regime as our clinic. RESULTS Twelve parameters had a significant correlation to HV (p<0.05) and a coefficient of determination >20%. Two parameters (In BA, In GHmax) showed a coefficient of determination >60% for children with GHD in multiple regression analysis. The validation of the mathematical model against another data set showed different results. GH was measured by the same method, but BA was scored at the first clinic as in our clinic by only one doctor and in the other university by several radiologists. The accuracy of prediction in the first clinic was significantly higher than in the other university. CONCLUSION This model demonstrates that exact scoring of BA and precise measurement of GHmax in the stimulation test is necessary, and if carried out carefully leads to useful prediction values for determining height velocity.
Collapse
Affiliation(s)
- V Mueller
- Department of Endocrinology and Auxology, Children's Hospital, University of Leipzig, Germany
| | | | | | | |
Collapse
|